>PA576967.1 WO 2023026994-A/15: Human transferrin receptor binding peptide-drug conjugate
AGAAAGACACAA
>PA576965.1 WO 2023026994-A/13: Human transferrin receptor binding peptide-drug conjugate
AGTGGCTAACAG
>PA576964.1 WO 2023026994-A/12: Human transferrin receptor binding peptide-drug conjugate
GTGGCTAACAGA
>PA576962.1 WO 2023026994-A/10: Human transferrin receptor binding peptide-drug conjugate
GAAATGGCGGCG
>PA576961.1 WO 2023026994-A/9: Human transferrin receptor binding peptide-drug conjugate
AAATGGCGGCGT
>pdb|8AUV|B Chain B, Cryo-EM structure of the plant 40S subunit
NTTTTTTTTTTT
>pdb|8G0Z|M Chain M, Mutant bacteriophage T4 gp41 helicase hexamer bound with single strand DNA and ATPgammaS in the stalled primosome
NTTTTTTTTTTT
>pdb|8DW6|M Chain M, T4 bacteriophage primosome with single-strand DNA, State 3
NTTTTTTTTTTT
>pdb|8DVI|M Chain M, T4 bacteriophage primosome with single strand DNA, State 2
NTTTTTTTTTTT
>pdb|8DVF|M Chain M, T4 Bacteriophage primosome with single strand DNA, state 1
NTTTTTTTTTTT
>OO465560.1 Sequence 64 from patent US 11421199
CCGGGGGGACAC
>OO465187.1 Sequence 16 from patent US 11421025
TCAGATTACTAC
>OO464937.1 Sequence 256 from patent US 11421011
CCGCCGCCGCCG
>OO313821.1 Sequence 15 from patent US 11377479
GGTCCTGGTCCT
>OO313442.1 Sequence 14 from patent US 11376290
AGGAAGAAGAGG
>OO313441.1 Sequence 12 from patent US 11376290
AAGAGGAGGAAG
>OO313440.1 Sequence 10 from patent US 11376290
AAGAAGAGGAGG
>OO313439.1 Sequence 8 from patent US 11376290
AGGAGGAAGAAG
>OO313438.1 Sequence 6 from patent US 11376290
AAGAGGAAGAGG
>OO313437.1 Sequence 4 from patent US 11376290
AGGAAGAGGAAG
>OO295923.1 Sequence 85 from patent US 11369670
GCCACCATGGCC
>OO295922.1 Sequence 84 from patent US 11369670
GCCACCATGGCT
>OO289194.1 Sequence 4 from patent US 11365413
TAACAAAATAAT
>OO289193.1 Sequence 3 from patent US 11365413
AAAAAAAAAAAA
>OO289191.1 Sequence 1 from patent US 11365413
AAAAAAAAAAAA
>OO287219.1 Sequence 36 from patent US 11365226
GTCACACAACTG
>OO097426.1 Sequence 19 from patent US 11312992
ACTTCAGCTGCC
>OO095390.1 Sequence 226 from patent US 11312965
NNNNCGNNNNCG
>OO095386.1 Sequence 222 from patent US 11312965
NNNCGCGNNNCG
>OO095382.1 Sequence 218 from patent US 11312965
NNNNNCGNNNNN
>OO095381.1 Sequence 217 from patent US 11312965
NNCGNNCGNNCG
>OO095363.1 Sequence 199 from patent US 11312965
TCGTCGAACGTT
>OO095362.1 Sequence 198 from patent US 11312965
TCGNNCGNNCGA
>OO497795.1 Sequence 70 from patent US 11427865
GCNGCCGCGGTA
>OO497794.1 Sequence 69 from patent US 11427865
GCMGCCGCGGTA
>OO497793.1 Sequence 68 from patent US 11427865
CNGCCGCGGTAA
>OO497792.1 Sequence 67 from patent US 11427865
CMGCCGCGGTAA
>OO497789.1 Sequence 64 from patent US 11427865
GTGNCAGCNGCC
>OO497788.1 Sequence 63 from patent US 11427865
GTGYCAGCMGCC
>OO497641.1 Sequence 4 from patent US 11427862
AAAGAAGACCCT
>OO497640.1 Sequence 3 from patent US 11427862
AAAGAAGACCCT
>OO477422.1 Sequence 1075 from patent US 11427837
GTTTTAGAGCTA
>OO474299.1 Sequence 26 from patent US 11427819
AGCTTAGGATCC
>OO472666.1 Sequence 304 from patent US 11427640
CCCTTGGACTCC
>OO471851.1 Sequence 9 from patent US 11422832
GTACTAGTACTA
>OO470895.1 Sequence 6 from patent US 11421274
GAACNNNNNCTC
>OO470891.1 Sequence 2 from patent US 11421274
CAANNNNNGTGG
>OO470581.1 Sequence 44 from patent US 11421268
TCTGCTCAACTA
>OO469886.1 Sequence 2095 from patent US 11421250
TAGATTGCTGTT
>OO469801.1 Sequence 1914 from patent US 11421250
TAGATTGCTGTT
>OO469357.1 Sequence 1470 from patent US 11421250
GTGCCAACGCGC
>OO469212.1 Sequence 1325 from patent US 11421250
ATTCGTGAAACG
>OO469208.1 Sequence 1321 from patent US 11421250
ATTCGTGAAACG
>OO469204.1 Sequence 1317 from patent US 11421250
ATTCGTGAAACG
>OO469201.1 Sequence 1314 from patent US 11421250
ATTCGTGAAACG
>OO459222.1 Sequence 10 from patent US 11414784
CGGCTTCCTGAT
>OO459221.1 Sequence 9 from patent US 11414784
CCGGCTTTCCAA
>OO459220.1 Sequence 8 from patent US 11414784
CCTCCTTCGACC
>OO459218.1 Sequence 6 from patent US 11414784
GACACCGGGCCC
>OO459215.1 Sequence 3 from patent US 11414784
TTCCCGATCCGA
>OO458858.1 Sequence 98 from patent US 11414710
GTGAGATCGTAC
>OO458857.1 Sequence 97 from patent US 11414710
ACTGTCATGCAG
>OO458856.1 Sequence 96 from patent US 11414710
ATCTGATGCGTA
>OO458855.1 Sequence 95 from patent US 11414710
GACACGCACTCT
>OO458854.1 Sequence 94 from patent US 11414710
TCAGACTCTAGT
>OO458853.1 Sequence 93 from patent US 11414710
TGTACAGTACAC
>OO458852.1 Sequence 92 from patent US 11414710
GCGAGTCATGCA
>OO458851.1 Sequence 91 from patent US 11414710
TAGCTCGAACTG
>OO458850.1 Sequence 90 from patent US 11414710
CTAGTGCAGCTA
>OO458849.1 Sequence 89 from patent US 11414710
TACATGAGCGAG
>OO458848.1 Sequence 88 from patent US 11414710
CTAGCTGTGAGT
>OO458847.1 Sequence 87 from patent US 11414710
AGTGACATCTGC
>OO458846.1 Sequence 86 from patent US 11414710
TGATGACGTAGC
>OO458845.1 Sequence 85 from patent US 11414710
CGTGTGACAGAG
>OO458844.1 Sequence 84 from patent US 11414710
ACGTGTATCAGC
>OO458843.1 Sequence 83 from patent US 11414710
CAGTAGTATGCT
>OO458842.1 Sequence 82 from patent US 11414710
ATACCGCTGATT
>OO458841.1 Sequence 81 from patent US 11414710
CTCGACTGATGA
>OO458840.1 Sequence 80 from patent US 11414710
GACTATCGCATG
>OO458839.1 Sequence 79 from patent US 11414710
ACGAGTGCTCTG
>OO458838.1 Sequence 78 from patent US 11414710
TAGCTAGAGTAC
>OO458837.1 Sequence 77 from patent US 11414710
CTCGACAGTCGA
>OO458836.1 Sequence 76 from patent US 11414710
GTATCATCATCA
>OO458835.1 Sequence 75 from patent US 11414710
GCTACTGCAGCT
>OO458834.1 Sequence 74 from patent US 11414710
GTACGATCTCAC
>OO458833.1 Sequence 73 from patent US 11414710
CTGCATGACAGT
>OO458832.1 Sequence 72 from patent US 11414710
TACGCATCAGAT
>OO458831.1 Sequence 71 from patent US 11414710
AGAGTGCGTGTC
>OO458830.1 Sequence 70 from patent US 11414710
ACTAGAGTCTGA
>OO458829.1 Sequence 69 from patent US 11414710
GTGTACTGTACA
>OO458828.1 Sequence 68 from patent US 11414710
TGCATGACTCGC
>OO458827.1 Sequence 67 from patent US 11414710
CAGTTCGAGCTA
>OO458826.1 Sequence 66 from patent US 11414710
TAGCTGCACTAG
>OO458825.1 Sequence 65 from patent US 11414710
CTCGCTCATGTA
>OO458824.1 Sequence 64 from patent US 11414710
ACTCACAGCTAG
>OO458823.1 Sequence 63 from patent US 11414710
GCAGATGTCACT
>OO458822.1 Sequence 62 from patent US 11414710
GCTACGTCATCA
>OO458821.1 Sequence 61 from patent US 11414710
CTCTGTCACACG
>OO458820.1 Sequence 60 from patent US 11414710
GCTGATACACGT
>OO458819.1 Sequence 59 from patent US 11414710
AGCATACTACTG
>OO458818.1 Sequence 58 from patent US 11414710
AATCAGCGGTAT
>OO458817.1 Sequence 57 from patent US 11414710
TCATCAGTCGAG
>OO458816.1 Sequence 56 from patent US 11414710
CATGCGATAGTC
>OO458815.1 Sequence 55 from patent US 11414710
CAGAGCACTCGT
>OO458814.1 Sequence 54 from patent US 11414710
GTACTCTAGCTA
>OO458813.1 Sequence 53 from patent US 11414710
TCGACTGTCGAG
>OO458812.1 Sequence 52 from patent US 11414710
TGATGATGATAC
>OO458811.1 Sequence 51 from patent US 11414710
AGCTGCAGTAGC
>OO456130.1 Sequence 128 from patent US 11414686
TGTGAGACACTG
>OO456128.1 Sequence 126 from patent US 11414686
TGTCTCTCACTG
>OO456126.1 Sequence 124 from patent US 11414686
TGTGTGTCTCTG
>OO456124.1 Sequence 122 from patent US 11414686
TGTGACAGACTG
>OO456122.1 Sequence 120 from patent US 11414686
TGTCACAGTCTG
>OO456120.1 Sequence 118 from patent US 11414686
TGTGAGTCTCTG
>OO456118.1 Sequence 116 from patent US 11414686
TGTGTGTCACTG
>OO456116.1 Sequence 114 from patent US 11414686
TGTGTCTGACTG
>OO456114.1 Sequence 112 from patent US 11414686
TGTCTCACTCTG
>OO456112.1 Sequence 110 from patent US 11414686
TGTCAGTCACTG
>OO456110.1 Sequence 108 from patent US 11414686
TGTCAGACTCTG
>OO456108.1 Sequence 106 from patent US 11414686
TGTGTCAGACTG
>OO456106.1 Sequence 104 from patent US 11414686
TGTCAGTGACTG
>OO456104.1 Sequence 102 from patent US 11414686
TGTCAGAGACTG
>OO456102.1 Sequence 100 from patent US 11414686
TGTCTGACTCTG
>OO456100.1 Sequence 98 from patent US 11414686
TGTGTCACTCTG
>OO456098.1 Sequence 96 from patent US 11414686
TGTCTGTGACTG
>OO456096.1 Sequence 94 from patent US 11414686
TGTGTCACACTG
>OO456094.1 Sequence 92 from patent US 11414686
TGTCAGAGTCTG
>OO456092.1 Sequence 90 from patent US 11414686
TGTCACTGACTG
>OO456090.1 Sequence 88 from patent US 11414686
TGTGACACACTG
>OO456088.1 Sequence 86 from patent US 11414686
TGTCTGTCTCTG
>OO456086.1 Sequence 84 from patent US 11414686
TGTGTGTGTCTG
>OO456084.1 Sequence 82 from patent US 11414686
TGTCTCTGTCTG
>OO456082.1 Sequence 80 from patent US 11414686
TGTGTGACACTG
>OO456080.1 Sequence 78 from patent US 11414686
TGTCTCACACTG
>OO456078.1 Sequence 76 from patent US 11414686
TGTGAGTGACTG
>OO456076.1 Sequence 74 from patent US 11414686
TGTCAGTCTCTG
>OO456074.1 Sequence 72 from patent US 11414686
TGTGAGAGTCTG
>OO456072.1 Sequence 70 from patent US 11414686
TGTCTGAGTCTG
>OO456070.1 Sequence 68 from patent US 11414686
TGTGACAGTCTG
>OO456068.1 Sequence 66 from patent US 11414686
TGTGTCAGTCTG
>OO456066.1 Sequence 64 from patent US 11414686
TGTCTGAGACTG
>OO456064.1 Sequence 62 from patent US 11414686
TGTCACTGTCTG
>OO456062.1 Sequence 60 from patent US 11414686
TGTCACACACTG
>OO456060.1 Sequence 58 from patent US 11414686
TGTCAGACACTG
>OO456058.1 Sequence 56 from patent US 11414686
TGTGTCTCTCTG
>OO456056.1 Sequence 54 from patent US 11414686
TGTCACAGACTG
>OO456054.1 Sequence 52 from patent US 11414686
TGTGTGAGACTG
>OO456052.1 Sequence 50 from patent US 11414686
TGTGTCTCACTG
>OO456050.1 Sequence 48 from patent US 11414686
TGTGTGAGTCTG
>OO456048.1 Sequence 46 from patent US 11414686
TGTCTGTCACTG
>OO456046.1 Sequence 44 from patent US 11414686
TGTGAGTGTCTG
>OO456044.1 Sequence 42 from patent US 11414686
TGTGAGACTCTG
>OO456042.1 Sequence 40 from patent US 11414686
TGTGACTGACTG
>OO456040.1 Sequence 38 from patent US 11414686
TGTCAGTGTCTG
>OO456038.1 Sequence 36 from patent US 11414686
TGTGTGACTCTG
>OO456036.1 Sequence 34 from patent US 11414686
TGTGACTCTCTG
>OO456034.1 Sequence 32 from patent US 11414686
TGTCTCTCTCTG
>OO456032.1 Sequence 30 from patent US 11414686
TGTCTGACACTG
>OO456030.1 Sequence 28 from patent US 11414686
TGTGTGTGACTG
>OO456028.1 Sequence 26 from patent US 11414686
TGTCTCTGACTG
>OO456026.1 Sequence 24 from patent US 11414686
TGTCTCAGTCTG
>OO456024.1 Sequence 22 from patent US 11414686
TGTCACTCTCTG
>OO456022.1 Sequence 20 from patent US 11414686
TGTGACTGTCTG
>OO456020.1 Sequence 18 from patent US 11414686
TGTCACTCACTG
>OO456018.1 Sequence 16 from patent US 11414686
TGTCTCAGACTG
>OO456016.1 Sequence 14 from patent US 11414686
TGTGAGTCACTG
>OO456014.1 Sequence 12 from patent US 11414686
TGTGTCTGTCTG
>OO456012.1 Sequence 10 from patent US 11414686
TGTGAGAGACTG
>OO456010.1 Sequence 8 from patent US 11414686
TGTGACACTCTG
>OO456008.1 Sequence 6 from patent US 11414686
TGTCACACTCTG
>OO456006.1 Sequence 4 from patent US 11414686
TGTCTGTGTCTG
>OO456004.1 Sequence 2 from patent US 11414686
TGTGACTCACTG
>OO455320.1 Sequence 13 from patent US 11414669
GCCGCCATGGCG
>OO454698.1 Sequence 2 from patent US 11414653
CGGNNNNNNCGG
>OO443722.1 Sequence 132 from patent US 11408004
GCTAGTCTGTTG
>OO443636.1 Sequence 46 from patent US 11408004
GTCTGATGGAGA
>OO443635.1 Sequence 45 from patent US 11408004
GTCTGATGGAGA
>OO443634.1 Sequence 44 from patent US 11408004
GTCTGATGGAGA
>OO443633.1 Sequence 43 from patent US 11408004
GTCTGATGGAGA
>OO443632.1 Sequence 42 from patent US 11408004
GTCTGATGGAGA
>OO420266.1 Sequence 58 from patent US 11407990
GCTCGCGATGCT
>OO420265.1 Sequence 57 from patent US 11407990
AGAGGGCTCTGC
>OO420220.1 Sequence 7 from patent US 11407990
GCTCGCGATGCT
>OO420219.1 Sequence 6 from patent US 11407990
AGAGGGCTCTGC
>OO420215.1 Sequence 2 from patent US 11407990
GCTCGCGATGCT
>OO420214.1 Sequence 1 from patent US 11407990
AGAGGGCTCTGC
>OO420039.1 Sequence 42 from patent US 11407985
GTTTTAGAGCTA
>OO416586.1 Sequence 40 from patent US 11405371
ATAAGAGACAGG
>OO416585.1 Sequence 39 from patent US 11405371
TATAAGAGACAG
>OO416584.1 Sequence 38 from patent US 11405371
GAATAAGAGACA
>OO416583.1 Sequence 37 from patent US 11405371
TGTATAAGAGAC
>OO416582.1 Sequence 36 from patent US 11405371
GTGTATAAGAGA
>OO416581.1 Sequence 35 from patent US 11405371
TGTGTATAAGAG
>OO416580.1 Sequence 34 from patent US 11405371
ATGTGTATAAGA
>OO416579.1 Sequence 33 from patent US 11405371
GATGTGTATAAG
>OO416578.1 Sequence 32 from patent US 11405371
AGATGTGTATAA
>OO416577.1 Sequence 31 from patent US 11405371
TAGATGTGTATA
>OO416576.1 Sequence 30 from patent US 11405371
CTAGATGTGTAT
>OO416575.1 Sequence 29 from patent US 11405371
TCTAGATGTGTA
>OO416574.1 Sequence 28 from patent US 11405371
ATCTAGATGTGT
>OO416573.1 Sequence 27 from patent US 11405371
CATCTAGATGTG
>OO416572.1 Sequence 26 from patent US 11405371
ACATCTAGATGT
>OO416571.1 Sequence 25 from patent US 11405371
CACATCTAGATG
>OO416570.1 Sequence 24 from patent US 11405371
ACACATCTAGAT
>OO416569.1 Sequence 23 from patent US 11405371
TACACATCTAGA
>OO416568.1 Sequence 22 from patent US 11405371
ATACACATCTAG
>OO416567.1 Sequence 21 from patent US 11405371
TATACACATCTA
>OO416566.1 Sequence 20 from patent US 11405371
TTATACACATCT
>OO416565.1 Sequence 19 from patent US 11405371
CTTATACACATC
>OO416564.1 Sequence 18 from patent US 11405371
TCTTATACACAT
>OO416563.1 Sequence 17 from patent US 11405371
CTCTTATACACA
>OO416562.1 Sequence 16 from patent US 11405371
TCTCTTATACAC
>OO416561.1 Sequence 15 from patent US 11405371
GTCTCTTATACA
>OO416560.1 Sequence 14 from patent US 11405371
TGTCTCTTATAC
>OO416559.1 Sequence 13 from patent US 11405371
CTGTCTCTTATA
>OO416558.1 Sequence 12 from patent US 11405371
AATAAGAGACAG
>OO416557.1 Sequence 11 from patent US 11405371
TAGAATAGACAG
>OO416556.1 Sequence 10 from patent US 11405371
CTTATACACATC
>OO416555.1 Sequence 9 from patent US 11405371
TTATACACATCT
>OO416554.1 Sequence 8 from patent US 11405371
AGATGTGTATAA
>OO416553.1 Sequence 7 from patent US 11405371
GATGTGTATAAG
>OO416552.1 Sequence 6 from patent US 11405371
ATGTGTATAAGA
>OO416551.1 Sequence 5 from patent US 11405371
TGTGTATAAGAG
>OO416550.1 Sequence 4 from patent US 11405371
GTGTATAAGAGA
>OO416549.1 Sequence 3 from patent US 11405371
TGTATAAGAGAC
>OO416548.1 Sequence 2 from patent US 11405371
GTATAAGAGACA
>OO416547.1 Sequence 1 from patent US 11405371
TATAAGAGACAG
>OO413986.1 Sequence 3 from patent US 11401548
TGATCGNNNNNN
>OO413984.1 Sequence 1 from patent US 11401548
CGATCATGATCG
>OO413671.1 Sequence 679 from patent US 11401532
GTTTTAGAGCTA
>OO411200.1 Sequence 70 from patent US 11401347
GATCCTGCCCGG
>OO411166.1 Sequence 2466 from patent US 11401346
CCANNNNNNTGG
>OO411162.1 Sequence 2462 from patent US 11401346
NNNNNNGAGACG
>OO411157.1 Sequence 2457 from patent US 11401346
GACNNNNNNGTC
>OO411151.1 Sequence 2451 from patent US 11401346
GCANNNNNNTCG
>OO411150.1 Sequence 2450 from patent US 11401346
GTATCCNNNNNN
>OO411149.1 Sequence 2449 from patent US 11401346
NNNNNNNGCGGG
>OO410154.1 Sequence 71 from patent US 11401305
AGCAGGAGCGGC
>OO410153.1 Sequence 70 from patent US 11401305
GCCGCTCCTGCT
>OO410152.1 Sequence 69 from patent US 11401305
GGCGGCTGGTGC
>OO410151.1 Sequence 68 from patent US 11401305
GCCGCTCCTGCT
>OO410041.1 Sequence 621 from patent US 11400169
ACAYNNNNNGTA
>OO410040.1 Sequence 620 from patent US 11400169
TACNNNNNRTGT
>OO410039.1 Sequence 619 from patent US 11400169
GACNNNNNNGTC
>OO410036.1 Sequence 616 from patent US 11400169
CCANNNNNNNTC
>OO410033.1 Sequence 613 from patent US 11400169
GACNNNNNNTGG
>OO410030.1 Sequence 610 from patent US 11400169
TGANNNNNNTCA
>OO410029.1 Sequence 609 from patent US 11400169
GACNNNNNNGTC
>OO409975.1 Sequence 326 from patent US 11400169
NNNNNNGTCTTC
>OO409974.1 Sequence 325 from patent US 11400169
GAAGACNNNNNN
>OO409955.1 Sequence 149 from patent US 11400169
CAANNNNNGTGG
>OO409918.1 Sequence 79 from patent US 11400169
NNNNNNGGATAC
>OO409917.1 Sequence 78 from patent US 11400169
GTATCCNNNNNN
>OO408583.1 Sequence 7585 from patent US 11400144
TTAGTTAGTTAG
>OO408570.1 Sequence 5854 from patent US 11400144
AGGATTGCTCCT
>OO408567.1 Sequence 5851 from patent US 11400144
AAAATAAAAAAA
>OO408455.1 Sequence 5732 from patent US 11400144
ATAAATAAATTA
>OO408385.1 Sequence 5661 from patent US 11400144
TGCTAAACCCCT
>OO408218.1 Sequence 5487 from patent US 11400144
AATGTAACCTCC
>OO408193.1 Sequence 5461 from patent US 11400144
AGTTTTTCCCTC
>OO408182.1 Sequence 5449 from patent US 11400144
GTCTAATTCTTT
>OO408108.1 Sequence 5370 from patent US 11400144
ATAGATACAAAG
>OO408102.1 Sequence 5364 from patent US 11400144
ACAATCACCTGC
>OO408100.1 Sequence 5362 from patent US 11400144
AAAATTGCCTCC
>OO407897.1 Sequence 5147 from patent US 11400144
TCTATGGCTCCT
>OO407709.1 Sequence 4951 from patent US 11400144
TAATTTTAAGCA
>OO407630.1 Sequence 4866 from patent US 11400144
CTTAAAGCCTCC
>OO407249.1 Sequence 4471 from patent US 11400144
AGGGGGCATAAC
>OO407005.1 Sequence 4222 from patent US 11400144
GAAGGGTTTAAT
>OO406967.1 Sequence 4183 from patent US 11400144
GGGTGGATTAAT
>OO406953.1 Sequence 4168 from patent US 11400144
GGAGAGGATGAT
>OO406951.1 Sequence 4166 from patent US 11400144
GGAGGATTGATT
>OO406763.1 Sequence 3968 from patent US 11400144
GAGGTCAATTTA
>OO406596.1 Sequence 3792 from patent US 11400144
GGAGGGTCTCTA
>OO406337.1 Sequence 3521 from patent US 11400144
ATCAAGATTTAA
>OO406303.1 Sequence 3482 from patent US 11400144
AACGGTGATGAT
>OO406282.1 Sequence 3457 from patent US 11400144
ATTTTCGATTTT
>OO406205.1 Sequence 3371 from patent US 11400144
TTAAAAATTCAT
>OO406108.1 Sequence 3272 from patent US 11400144
AAAAAGAGTTTA
>OO406041.1 Sequence 3202 from patent US 11400144
ATTGACTTTAAA
>OO405973.1 Sequence 3131 from patent US 11400144
ATTAATTCCTTT
>OO405487.1 Sequence 2645 from patent US 11400144
GAATTCTAATTC
>OO405462.1 Sequence 2620 from patent US 11400144
TGCTTTTGAGCA
>OO405301.1 Sequence 2459 from patent US 11400144
GCACAATTGTGC
>OO405179.1 Sequence 2337 from patent US 11400144
GAGATATATCTC
>OO404822.1 Sequence 1980 from patent US 11400144
GGACATCTGTCC
>OO402675.1 Sequence 40 from patent US 11400110
GTTTTTGTACTC
>OO402669.1 Sequence 27 from patent US 11400110
AAATCATTTGAG
>OO402668.1 Sequence 26 from patent US 11400110
AATTCATTTGAG
>OO267727.1 Sequence 7 from patent US 11352667
CTTCGCTAACCC
>OO267641.1 Sequence 1274 from patent US 11352666
TATGCGTGGGAG
>OO267629.1 Sequence 1261 from patent US 11352666
GTTGTGGCAGCG
>OO264925.1 Sequence 68 from patent US 11352641
ATTTATCAGATT
>OO264924.1 Sequence 67 from patent US 11352641
AATCTGATAAAT
>OO264848.1 Sequence 68 from patent US 11352640
ATTTATCAGATT
>OO264847.1 Sequence 67 from patent US 11352640
AATCTGATAAAT
>OO257463.1 Sequence 1178 from patent US 11352409
AATCTAGAGATC
>OO257343.1 Sequence 898 from patent US 11352409
GACTTTGACTTG
>OO257323.1 Sequence 818 from patent US 11352409
AATCTAGAGATC
>OO257303.1 Sequence 778 from patent US 11352409
AATTTTGAGTTG
>OO257283.1 Sequence 738 from patent US 11352409
AATTTTGACTTG
>OO256865.1 Sequence 67 from patent US 11351273
GTTCGTCTGTCC
>OO256862.1 Sequence 64 from patent US 11351273
TGCGTCATCTCA
>OO256811.1 Sequence 13 from patent US 11351273
GTTCGTCTGTCC
>OO256800.1 Sequence 2 from patent US 11351273
GTTCGTCTGTCC
>OO256775.1 Sequence 56 from patent US 11351271
TTCANNGTCTTC
>OO256774.1 Sequence 55 from patent US 11351271
GAAGACNNATAA
>OO256770.1 Sequence 51 from patent US 11351271
TTCAAGAAGAGC
>OO256768.1 Sequence 49 from patent US 11351271
ATAANNGTCTTC
>OO256767.1 Sequence 48 from patent US 11351271
GAAGACNNCACC
>OO256763.1 Sequence 44 from patent US 11351271
GCTCTTCNCACC
>OO256762.1 Sequence 43 from patent US 11351271
CACCNNGTCTTC
>OO256761.1 Sequence 42 from patent US 11351271
GAAGACNNGACT
>OO252972.1 Sequence 194 from patent US 11345915
CNGGCNGGCNGG
>OO252971.1 Sequence 193 from patent US 11345915
NAGGNAGGNAGG
>OO252956.1 Sequence 178 from patent US 11345915
NGGNGGNGGNGG
>OO252946.1 Sequence 168 from patent US 11345915
GGNGGNGGNGGN
>OO252927.1 Sequence 148 from patent US 11345915
NNCNNCNNCNNC
>OO252926.1 Sequence 147 from patent US 11345915
TTNTTNTTNTTN
>OO252913.1 Sequence 134 from patent US 11345915
CNGCNGCNGCNG
>OO252912.1 Sequence 133 from patent US 11345915
NNGNNGNNGNNG
>OO252899.1 Sequence 120 from patent US 11345915
NGCNGCNGCNGC
>OO252898.1 Sequence 119 from patent US 11345915
NGNNGNNGNNGN
>OO252842.1 Sequence 63 from patent US 11345915
NNGGNNGGNNGG
>OO252828.1 Sequence 49 from patent US 11345915
NGGNGGNGGNGG
>OO252819.1 Sequence 40 from patent US 11345915
GGNGGNGGNGGN
>OO252810.1 Sequence 22 from patent US 11345915
NNGNNGNNGNNG
>OO252801.1 Sequence 13 from patent US 11345915
NGNNGNNGNNGN
>OO252792.1 Sequence 4 from patent US 11345915
NNGNNGNNGNNG
>OO240598.1 Sequence 26 from patent US 11344633
GGGGTTTTGGGG
>OO240186.1 Sequence 17 from patent US 11344589
GCTAGCGAATTC
>OO237002.1 Sequence 38 from patent US 11339437
AAGGCTAGTCCG
>OO232551.1 Sequence 3 from patent US 11339396
CCTGGATGGGAA
>OO230733.1 Sequence 18 from patent US 11339391
AAGGTAGACCCT
>OO230732.1 Sequence 17 from patent US 11339391
CTCTACTCGTGA
>OO230731.1 Sequence 16 from patent US 11339391
GCTACGAGTATC
>OO230730.1 Sequence 15 from patent US 11339391
TGACGTCTAGAG
>OO230729.1 Sequence 14 from patent US 11339391
AAGGTAGACCCT
>OO230728.1 Sequence 13 from patent US 11339391
CTCTACTCGTGA
>OO230727.1 Sequence 12 from patent US 11339391
GCTACGAGTATC
>OO230726.1 Sequence 11 from patent US 11339391
TGACGTCTAGAG
>OO230725.1 Sequence 10 from patent US 11339391
AAGGTAGACCCT
>OO230618.1 Sequence 28 from patent US 11339388
CGGCTTCCTGAT
>OO230617.1 Sequence 27 from patent US 11339388
CCGGCTTTCCAA
>OO230616.1 Sequence 26 from patent US 11339388
CCTCCTTCGACC
>OO230614.1 Sequence 24 from patent US 11339388
GACACCGGGCCC
>OO230611.1 Sequence 21 from patent US 11339388
TTCCCGATCCGA
>OO183257.1 Sequence 5 from patent US 11332778
CCTATCCCCTGT
>OO183253.1 Sequence 1 from patent US 11332778
CCATCTCATCCC
>OO182901.1 Sequence 679 from patent US 11332761
GTTTTAGAGCTA
>OO181199.1 Sequence 18 from patent US 11332756
AGCAAAAGCAGG
>OO173306.1 Sequence 5 from patent US 11332737
TGCATGATTACG
>OO169715.1 Sequence 5 from patent US 11326209
TANGGNNNNNNN
>OO169695.1 Sequence 4 from patent US 11326206
GTCAGTCAGTCA
>OO169234.1 Sequence 14 from patent US 11326201
GGTTCACCTACG
>OO169233.1 Sequence 13 from patent US 11326201
GGTTCGTCTACG
>OO168956.1 Sequence 902 from patent US 11326182
CGGGCCAAGCGG
>OO162997.1 Sequence 118 from patent US 11326165
CAGTAAGTCTGN
>OO162993.1 Sequence 114 from patent US 11326165
GCGCTGTGTCGA
>OO162945.1 Sequence 66 from patent US 11326165
GTTCTCAGTGTG
>OO162926.1 Sequence 47 from patent US 11326165
CGGGTCATAATC
>OO162058.1 Sequence 270 from patent US 11325967
GATCTTGACTTG
>OO160971.1 Sequence 332 from patent US 11325948
GCCGCCACCATG
>OO160814.1 Sequence 5 from patent US 11324824
GGSGGTGGSGGT
>OO402218.1 Sequence 119 from patent US 11396677
GGGGAAAATTTT
>OO398114.1 Sequence 10 from patent US 11395855
TTTTTTTTTTTT
>OO350700.1 Sequence 3 from patent US 11393558
TACTGCTCTAGA
>OO350699.1 Sequence 2 from patent US 11393558
TCTAGAGCAGTA
>OO350515.1 Sequence 19 from patent US 11390920
TCGATGTACAGC
>OO350514.1 Sequence 18 from patent US 11390920
TCTAGACTCGAG
>OO350511.1 Sequence 15 from patent US 11390920
TACGTCTGAGCA
>OO350256.1 Sequence 32 from patent US 11390904
TTTTTTTTTTTT
>OO348593.1 Sequence 38 from patent US 11390887
AAGGCTAGTCCG
>OO348476.1 Sequence 38 from patent US 11390884
AAGGCTAGTCCG
>OO348349.1 Sequence 52 from patent US 11390879
CACGACGAGCTG
>OO348348.1 Sequence 51 from patent US 11390879
AAGGACGAGCTG
>OO346674.1 Sequence 33 from patent US 11390867
GCTTTCCACGCA
>OO346668.1 Sequence 26 from patent US 11390867
TCCACGCACAGT
>OO346662.1 Sequence 18 from patent US 11390867
CTACGCTTTCCA
>OO345380.1 Sequence 22 from patent US 11389531
GCCGGAGCTGGC
>OO345161.1 Sequence 3 from patent US 11389525
CGGCGGAAGCGG
>OO342118.1 Sequence 99 from patent US 11384400
CCAGAGCAAGAG
>OO341806.1 Sequence 30 from patent US 11384396
TACTGTGGTTTA
>OO340804.1 Sequence 7 from patent US 11384363
AACGACAGCGTT
>OO340803.1 Sequence 6 from patent US 11384363
AAAGAAAGAGTT
>OO340466.1 Sequence 404 from patent US 11384361
TCAACACACAGA
>OO340456.1 Sequence 394 from patent US 11384361
CACAGAGAATGG
>OO340445.1 Sequence 383 from patent US 11384361
ATTCAACATACA
>OO339652.1 Sequence 73 from patent US 11384356
NNNNGCCTGTTG
>OO339581.1 Sequence 88 from patent US 11384355
TGACCATCGAAT
>OO339566.1 Sequence 71 from patent US 11384355
TATGGCTGTGCT
>OO339559.1 Sequence 64 from patent US 11384355
TATATATCATCA
>OO339544.1 Sequence 48 from patent US 11384355
TGACCATCGAAT
>OO339530.1 Sequence 32 from patent US 11384355
TATGGCTGTGCT
>OO339523.1 Sequence 25 from patent US 11384355
TATATATCATCA
>OO339345.1 Sequence 198 from patent US 11384353
GTTTGAGAGCTA
>OO339344.1 Sequence 197 from patent US 11384353
GTTTTAGAGCTA
>OO338780.1 Sequence 937 from patent US 11384344
GTGGGTTGAAAG
>OO338778.1 Sequence 935 from patent US 11384344
GTGGGTTGAAAG
>OO338776.1 Sequence 933 from patent US 11384344
GTGGGTTGAAAG
>OO338774.1 Sequence 931 from patent US 11384344
GTGGGTTGAAAG
>OO337090.1 Sequence 49 from patent US 11384133
CTCGAGATCTGA
>OO336906.1 Sequence 188 from patent US 11384122
GGTGGCAGCGGC
>OO336905.1 Sequence 187 from patent US 11384122
AGACGGGCCAGA
>OO336903.1 Sequence 185 from patent US 11384122
GGCAGCGGCGGC
>OO336657.1 Sequence 13 from patent US 11382986
TCTGCTTTCCCG
>OO336655.1 Sequence 8 from patent US 11382986
AAAGAGGCAGCA
>OO336654.1 Sequence 7 from patent US 11382986
GTCAGGGCTACG
>OO336653.1 Sequence 6 from patent US 11382986
GCTTGACCGTTA
>OO336652.1 Sequence 5 from patent US 11382986
CGAAGGTGGCAA
>OO336651.1 Sequence 4 from patent US 11382986
TGCTGCCTCTTT
>OO336650.1 Sequence 3 from patent US 11382986
CGTAGCCCTGAC
>OO336649.1 Sequence 2 from patent US 11382986
TAACGGTCAAGC
>OO336648.1 Sequence 1 from patent US 11382986
TTGCCACCTTCG
>OO335543.1 Sequence 12 from patent US 11377696
GGCGGCGGCGGC
>OO335542.1 Sequence 11 from patent US 11377696
GGCGGCGGCGGC
>OO332057.1 Sequence 16 from patent US 11377682
TTTGGTGTTTAT
>OO303708.1 Sequence 376 from patent US 11371101
GCCACCCCACTC
>OO303706.1 Sequence 374 from patent US 11371101
CGGTGGCATTGG
>OO303704.1 Sequence 372 from patent US 11371101
GAGCCAAACGCC
>OO303692.1 Sequence 360 from patent US 11371101
CAGCGTTCCCGG
>OO303536.1 Sequence 204 from patent US 11371101
GCCACCCCACTC
>OO303506.1 Sequence 174 from patent US 11371101
GAGCCAAACGCC
>OO303488.1 Sequence 156 from patent US 11371101
AGAACCAGCAGC
>OO303467.1 Sequence 135 from patent US 11371101
TCCAGCAGAGCT
>OO303422.1 Sequence 90 from patent US 11371101
TGCGGGTACTGG
>OO303356.1 Sequence 24 from patent US 11371101
CAGCGTTCCCGG
>OO303110.1 Sequence 85 from patent US 11371084
CCCCGCCCCGCG
>OO301616.1 Sequence 34 from patent US 11371051
TTACTGCATCGA
>OO301598.1 Sequence 16 from patent US 11371051
TTACTGCATCGA
>OO301593.1 Sequence 11 from patent US 11371051
TTACTGCATCGA
>OO301537.1 Sequence 190 from patent US 11371050
AGAGGAAGAGGN
>OO301535.1 Sequence 188 from patent US 11371050
NTGTCAGGGCTT
>OO301287.1 Sequence 221 from patent US 11371045
CTGATTCTCACG
>OO300350.1 Sequence 233 from patent US 11371031
TTTTTTTTTTTT
>OO300216.1 Sequence 2 from patent US 11371027
ACTACGAACGCG
>OO300215.1 Sequence 1 from patent US 11371027
ACTACGAACGCG
>OO300037.1 Sequence 88 from patent US 11370846
GGGGACGGCATC
>OO269358.1 Sequence 21 from patent US 11357790
CGCCATGCTGCT
>OO159142.1 Sequence 1 from patent US 11322225
GCAGCTGTTTCG
>OO158257.1 Sequence 24 from patent US 11320376
TAAAAGGTGTAC
>OO158250.1 Sequence 17 from patent US 11320376
TCCTGAGTCAAC
>OO158249.1 Sequence 16 from patent US 11320376
CAGAGCTTACAT
>OO158248.1 Sequence 15 from patent US 11320376
CGAAATACCCTG
>OO158247.1 Sequence 14 from patent US 11320376
TGTTCTACCGAG
>OO158246.1 Sequence 13 from patent US 11320376
CGCTAAATCCTG
>OO158245.1 Sequence 12 from patent US 11320376
TCCTGAGTCAAC
>OO158244.1 Sequence 11 from patent US 11320376
GAAAACACCGTC
>OO158243.1 Sequence 10 from patent US 11320376
GCTCTGTTAAGT
>OO158242.1 Sequence 9 from patent US 11320376
CAGAGCTTACAT
>OO158241.1 Sequence 8 from patent US 11320376
TACACTGGACAT
>OO158240.1 Sequence 7 from patent US 11320376
TTATATGCCACG
>OO158239.1 Sequence 6 from patent US 11320376
ACACAAGCTACA
>OO149723.1 Sequence 28 from patent US 11319589
CGTACGTACGTG
>OO149722.1 Sequence 27 from patent US 11319589
CGTACGTACGTC
>OO149721.1 Sequence 26 from patent US 11319589
CGTACGTACGTT
>OO149720.1 Sequence 25 from patent US 11319589
CGTACGTACGTA
>OO149718.1 Sequence 23 from patent US 11319589
CGTACGTACGTA
>OO149716.1 Sequence 21 from patent US 11319589
CGTACGTACGTA
>OO149714.1 Sequence 19 from patent US 11319589
CGTACGTACGTC
>OO149713.1 Sequence 18 from patent US 11319589
CGTACGTACGTT
>OO149712.1 Sequence 17 from patent US 11319589
DGTACGTACGTA
>OO149709.1 Sequence 14 from patent US 11319589
CGTACGTACGTA
>OO148872.1 Sequence 105 from patent US 11319549
TGTCTAATTAGT
>OO144934.1 Sequence 177 from patent US 11319380
AGTGGCAGCGGC
>OO144930.1 Sequence 172 from patent US 11319380
CGTGCAAAGCGT
>OO144263.1 Sequence 1 from patent US 11319349
CTGCTGCTGCTG
>OO143660.1 Sequence 308 from patent US 11316812
TTATAAGTCCAG
>OO143124.1 Sequence 732 from patent US 11315659
TTGCCACAGGGC
>OO095270.1 Sequence 103 from patent US 11312965
TCGAACGTTCGA
>OO080422.1 Sequence 679 from patent US 11312953
GTTTTAGAGCTA
>OO079540.1 Sequence 20 from patent US 11312779
AGCCATCAGCTG
>OO079539.1 Sequence 19 from patent US 11312779
TAGCTTGAGTCT
>OO079538.1 Sequence 18 from patent US 11312779
ATGGCTTAGCTT
>OO076547.1 Sequence 1 from patent US 11311586
CTCGGTTATGGG
>OO076432.1 Sequence 178 from patent US 11311574
GAAGTCTGCCGT
>OO076418.1 Sequence 157 from patent US 11311574
AAAGCGGCTCCG
>OO076417.1 Sequence 152 from patent US 11311574
ACTCTGTGGAAG
>OO076402.1 Sequence 114 from patent US 11311574
ACTCTGTGGAAG
>OO076389.1 Sequence 84 from patent US 11311574
AACTCGGATAAT
>OO076382.1 Sequence 73 from patent US 11311574
AAGGTGAACGTG
>OO076381.1 Sequence 68 from patent US 11311574
GGGCAGTAACGG
>OO076374.1 Sequence 53 from patent US 11311574
TACAAGAACTCG
>OO076372.1 Sequence 43 from patent US 11311574
AACTCGGATAAT
>OO076365.1 Sequence 32 from patent US 11311574
GCGGCGCCGGCG
>OO076364.1 Sequence 27 from patent US 11311574
CATGGGGTTCCT
>pdb|8GAO|M Chain M, bacteriophage T4 stalled primosome with mutant gp41-E227Q
NTTTTTTTTTTT
>pdb|8CE2|B Chain B, X-ray structure of the adduct formed upon reaction of a B-DNA double helical dodecamer with dirhodium tetraacetate
CGCGAATTCGCG
>pdb|8CE2|A Chain A, X-ray structure of the adduct formed upon reaction of a B-DNA double helical dodecamer with dirhodium tetraacetate
CGCGAATTCGCG
>pdb|8FOH|T Chain T, Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex in the RNA synthesis state
NCTGCCGCCGCC
>pdb|8HTX|F Chain F, Crystal structure of BANP in complex with methylated DNA
CTCTNGCGAGAG
>pdb|8HTX|E Chain E, Crystal structure of BANP in complex with methylated DNA
CTCTNGCGAGAG
>pdb|8HTX|D Chain D, Crystal structure of BANP in complex with methylated DNA
CTCTNGCGAGAG
>pdb|8HTX|C Chain C, Crystal structure of BANP in complex with methylated DNA
CTCTNGCGAGAG
>pdb|7YUN|D Chain D, Crystal structure of human BEND6 BEN domain in complex with methylated DNA
CTCTCGNGAGAG
>pdb|7YUN|C Chain C, Crystal structure of human BEND6 BEN domain in complex with methylated DNA
CTCTCGNGAGAG
>pdb|7YUL|C Chain C, Crystal structure of human BEND6 BEN domain in complex with DNA
CTCTCGCGAGAG
>pdb|7YUK|D Chain D, Complex structure of BANP BEN domain bound to DNA
CTCTCGCGAGAG
>pdb|7YUK|C Chain C, Complex structure of BANP BEN domain bound to DNA
CTCTCGCGAGAG
>pdb|7Z9P|F Chain F, The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
CGCGAATTCGCG
>pdb|7Z9P|E Chain E, The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
CGCGAATTCGCG
>pdb|7Z9P|D Chain D, The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
CGCGAATTCGCG
>pdb|7Z9P|C Chain C, The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
CGCGAATTCGCG
>pdb|7Z9P|B Chain B, The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
CGCGAATTCGCG
>pdb|7Z9P|A Chain A, The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic
CGCGAATTCGCG
>pdb|8CUC|D Chain D, Crystal structure analysis of SALL4 zinc finger domain in complex with DNA
NCTAATATTTCG
>pdb|8CUC|C Chain C, Crystal structure analysis of SALL4 zinc finger domain in complex with DNA
NGAAATATTAGC
>pdb|8CUC|B Chain B, Crystal structure analysis of SALL4 zinc finger domain in complex with DNA
NCTAATATTTCG
>pdb|8CUC|A Chain A, Crystal structure analysis of SALL4 zinc finger domain in complex with DNA
NGAAATATTAGC
>pdb|7YGP|A Chain A, DNA duplex containing 5OHU-T base pairs
GGACCTNGGTCC
>pdb|7YGO|A Chain A, DNA duplex containing 5OHU-Hg(II)-T base pairs
GGACCTNGGTCC
>pdb|5HAW|Z Chain Z, structures of the NO factor SlmA bound to DNA and the cytoskeletal cell division protein FtsZ
GTGAGTACTCAC
>pdb|8FOG|T Chain T, Crystal structure of human DNA polymerase eta incorporating dITP across dT
CATTCTCACACT
>pdb|8FN3|T Chain T, Crystal structure of human DNA polymerase eta incorporating dITP across dC
CATCCTCACACT
>pdb|7Y8P|B Chain B, Crystal structure of 4'-selenoRNA duplex
GGANNNGAGTCC
>pdb|7Y8P|A Chain A, Crystal structure of 4'-selenoRNA duplex
GGANNNGAGTCC
>PA571563.1 JP 2023005283-A/47: Metabolite production using a protein added with a peptide tag
CGAAAACCAGGT
>PA571556.1 JP 2023005283-A/40: Metabolite production using a protein added with a peptide tag
CGAAATAAACCA
>PA571555.1 JP 2023005283-A/39: Metabolite production using a protein added with a peptide tag
GCTAATAAACCA
>PA571562.1 JP 2023005283-A/46: Metabolite production using a protein added with a peptide tag
CGAAATAAACAA
>PA571561.1 JP 2023005283-A/45: Metabolite production using a protein added with a peptide tag
CGAAATAAAGAT
>PA571560.1 JP 2023005283-A/44: Metabolite production using a protein added with a peptide tag
CTTAATAAACCA
>PA571559.1 JP 2023005283-A/43: Metabolite production using a protein added with a peptide tag
GTTAATAAAGAA
>PA571558.1 JP 2023005283-A/42: Metabolite production using a protein added with a peptide tag
CGAAATCCAGGT
>PA571557.1 JP 2023005283-A/41: Metabolite production using a protein added with a peptide tag
GTTAATAAACCA
>pdb|8AMD|D Chain D, Cryo-EM structure of the RecA presynaptic filament from S.pneumoniae
TTTTTTTTTTTT
>pdb|1Z1C|B Chain B, Structural Determinants of Tissue Tropism and In Vivo Pathogenicity for the Parvovirus Minute virus of Mice
ATCCTCTATCAC
>OO076187.1 Sequence 308 from patent US 11310180
TTATAAGTCCAG
>OO076066.1 Sequence 308 from patent US 11310179
TTATAAGTCCAG
>OO074436.1 Sequence 1 from patent US 11306355
GTCGACCGGATC
>OO074359.1 Sequence 22 from patent US 11306348
GGATATGCTCGG
>OO066701.1 Sequence 12 from patent US 11305007
AAAGCAGCCGCA
>OO066700.1 Sequence 11 from patent US 11305007
GGCGCAGCAGCC
>OO066496.1 Sequence 124 from patent US 11304978
CGGGCCAAGCGG
>OO066490.1 Sequence 118 from patent US 11304978
AGGGCTAAACGG
>OO066471.1 Sequence 97 from patent US 11304978
CGGGCCAAGCGG
>OO066465.1 Sequence 91 from patent US 11304978
AGGGCTAAACGG
>OO066446.1 Sequence 70 from patent US 11304978
CGGGCCAAGCGG
>OO066440.1 Sequence 64 from patent US 11304978
AGGGCTAAACGG
>OO066434.1 Sequence 57 from patent US 11304978
AGAGCAAAGCGG
>OO066415.1 Sequence 36 from patent US 11304978
CGGGCCAAGCGG
>OO066409.1 Sequence 30 from patent US 11304978
AGGGCTAAACGG
>OO066389.1 Sequence 8 from patent US 11304978
CGGGCCAAGCGG
>OO065385.1 Sequence 308 from patent US 11303594
TTATAAGTCCAG
>OO065264.1 Sequence 308 from patent US 11303593
TTATAAGTCCAG
>OO065143.1 Sequence 308 from patent US 11303592
TTATAAGTCCAG
>OO064954.1 Sequence 13 from patent US 11300572
TGTTTTAATAAA
>OO064724.1 Sequence 11 from patent US 11299777
GCATGCATGCAT
>OO064723.1 Sequence 10 from patent US 11299777
ATGCATGCATGC
>OO064523.1 Sequence 101 from patent US 11299766
GACGAACGCACG
>OO064520.1 Sequence 98 from patent US 11299766
ATAGTGTTGTGG
>OO064517.1 Sequence 95 from patent US 11299766
GTTCGTTTATCG
>OO064514.1 Sequence 92 from patent US 11299766
CGGTTTTTTGCG
>OO064511.1 Sequence 89 from patent US 11299766
CGGCGTTCGCGA
>OO064507.1 Sequence 85 from patent US 11299766
ATCGGTTTCGTT
>OO064283.1 Sequence 902 from patent US 11299751
CGGGCCAAGCGG
>OO063316.1 Sequence 3 from patent US 11299739
TTCTTAGCGTTT
>OO063190.1 Sequence 90 from patent US 11299736
GCATTGGTATTC
>OO063080.1 Sequence 17 from patent US 11299735
CNCACCNGGAGC
>OO063073.1 Sequence 7 from patent US 11299735
NCACCNGGAGCA
>OO062519.1 Sequence 66 from patent US 11299720
AACCGGTTAACC
>OO062518.1 Sequence 65 from patent US 11299720
ACGTACGTACGT
>OO062506.1 Sequence 24 from patent US 11299719
TTCTNANCGTTT
>OO062505.1 Sequence 23 from patent US 11299719
TTCNTANCGTTT
>OO062504.1 Sequence 22 from patent US 11299719
TTCNNAGCGTTT
>OO062503.1 Sequence 21 from patent US 11299719
TTCTTANCGTTT
>OO062502.1 Sequence 20 from patent US 11299719
TTCTNAGCGTTT
>OO062501.1 Sequence 19 from patent US 11299719
TTCNTAGCGTTT
>OO062500.1 Sequence 18 from patent US 11299719
TTCTTAGCGTTT
>OO061867.1 Sequence 19 from patent US 11299511
CGCCCTTCTCAG
>OO061866.1 Sequence 18 from patent US 11299511
CCCTTCTCAGTT
>OO059191.1 Sequence 5 from patent US 11298328
SNGSGGGCAMCC
>OO010401.1 Sequence 679 from patent US 11293034
GTTTTAGAGCTA
>OO003571.1 Sequence 93 from patent US 11292846
GAGTTCGACTAT
>OO003564.1 Sequence 79 from patent US 11292846
GACTTCGACTAT
>OO003544.1 Sequence 46 from patent US 11292846
GAGTTCGACTAT
>OO003530.1 Sequence 18 from patent US 11292846
GACTTCGACTAT
>pdb|8AM9|X Chain X, Cryo-EM structure of the proline-rich antimicrobial peptide drosocin bound to the elongating ribosome
NGTATGTTGATA
>MY953011.1 Sequence 7 from patent US 11286518
AATCAGTCTCGT
>MY946491.1 Sequence 37 from patent US 11286482
CCAGGTAAGTAT
>MY946186.1 Sequence 9 from patent US 11286309
AAGCTTGCCACC
>MY945895.1 Sequence 10 from patent US 11286275
GCGTTNTTTGCT
>MY945888.1 Sequence 3 from patent US 11286275
GCGTTNTTTGCT
>MY945887.1 Sequence 2 from patent US 11286275
GCGTTNTTTGCT
>MY945886.1 Sequence 1 from patent US 11286275
AGCAAANAACGC
>MY944935.1 Sequence 3 from patent US 11281856
TCGGCGGGCTAA
>MY944782.1 Sequence 3 from patent US 11279979
TTTCTCCTGATT
>MY944372.1 Sequence 42 from patent US 11279969
GAGGGTTTTAAG
>MY944371.1 Sequence 41 from patent US 11279969
ATGTTGTGGGTA
>MY944370.1 Sequence 40 from patent US 11279969
GAGTTGGATGAG
>MY944369.1 Sequence 39 from patent US 11279969
ATGGGAAAAAGT
>MY944368.1 Sequence 38 from patent US 11279969
GTTAGTGGGAAA
>MY944367.1 Sequence 37 from patent US 11279969
TTTGGGTTTAGG
>MY944366.1 Sequence 36 from patent US 11279969
GTTGTTATTGTG
>MY944365.1 Sequence 35 from patent US 11279969
TGAGAAGGGTAG
>MY944364.1 Sequence 34 from patent US 11279969
AGCGTGGAAAAG
>MY944363.1 Sequence 33 from patent US 11279969
GAGGGCGAAAAG
>MY944362.1 Sequence 32 from patent US 11279969
CGAGAGGAAAAG
>MY944361.1 Sequence 31 from patent US 11279969
AGCCGAGAAAAG
>MY944360.1 Sequence 30 from patent US 11279969
GTGAGGGAAAAG
>MY944359.1 Sequence 29 from patent US 11279969
GGGGATGAAAAG
>MY944358.1 Sequence 28 from patent US 11279969
GAAGGAGAAAAG
>MY944357.1 Sequence 27 from patent US 11279969
TGGATGGAAAAG
>MY944356.1 Sequence 26 from patent US 11279969
AGGGTGGATGAC
>MY944355.1 Sequence 25 from patent US 11279969
AGCCGAGATGAC
>MY944354.1 Sequence 24 from patent US 11279969
AGTGGGGAGGAG
>MY944353.1 Sequence 23 from patent US 11279969
AGAGGGGATGAC
>MY944352.1 Sequence 22 from patent US 11279969
AGGGGTGAGGAG
>MY944351.1 Sequence 21 from patent US 11279969
AGGAGTGATGAC
>MY944350.1 Sequence 20 from patent US 11279969
GTATCGGATGAC
>MY944349.1 Sequence 19 from patent US 11279969
AGGACAGATGAC
>MY943606.1 Sequence 27 from patent US 11279939
TGGAAAATTCCA
>MY939107.1 Sequence 1097 from patent US 11279926
GTTTTAGAGCTA
>MY939104.1 Sequence 1094 from patent US 11279926
GTTTAAGAGCTA
>MY939089.1 Sequence 1079 from patent US 11279926
GTTTTAGAGCTA
>MY938819.1 Sequence 3091 from patent US 11279925
TATNNNNNNCTG
>MY938785.1 Sequence 3057 from patent US 11279925
CCGGGTCTGTGG
>MY938766.1 Sequence 3038 from patent US 11279925
GACATCAACAAC
>MY938765.1 Sequence 3037 from patent US 11279925
CGTCGTCGTGGT
>MY938729.1 Sequence 3001 from patent US 11279925
CGCCGCCGCCTG
>MY938728.1 Sequence 3000 from patent US 11279925
CGCAAAAAACTG
>MY938705.1 Sequence 2977 from patent US 11279925
CAGCGTGTTCTG
>MY938558.1 Sequence 2690 from patent US 11279925
AGCATTCTGAAA
>MY938557.1 Sequence 2689 from patent US 11279925
CGCGTGNNNTTT
>MY938420.1 Sequence 2552 from patent US 11279925
AGCATTCTGAAA
>MY938419.1 Sequence 2551 from patent US 11279925
CGCGTGNNNTTT
>MY938281.1 Sequence 2413 from patent US 11279925
AGCATTCTGAAA
>MY938280.1 Sequence 2412 from patent US 11279925
CGCGTGNNNTTT
>MY938204.1 Sequence 2336 from patent US 11279925
AGCATTCTGAAA
>MY938203.1 Sequence 2335 from patent US 11279925
CGCGTGNNNTTT
>MY938107.1 Sequence 2239 from patent US 11279925
AGCATTCTGAAA
>MY938106.1 Sequence 2238 from patent US 11279925
CGCGTGNNNTTT
>MY937981.1 Sequence 137 from patent US 11279925
GACATCAACAAC
>MY937980.1 Sequence 136 from patent US 11279925
GACATCAACAAC
>MY937979.1 Sequence 134 from patent US 11279925
AGAAGAAGAGGC
>MY937978.1 Sequence 133 from patent US 11279925
CGTCGTCGTGGT
>MY937955.1 Sequence 101 from patent US 11279925
CAGAGAGTTCTG
>MY937954.1 Sequence 100 from patent US 11279925
CAGCGTGTTCTG
>MY936649.1 Sequence 86 from patent US 11279739
CAGCAGCAGCAG
>MY936525.1 Sequence 3 from patent US 11279708
CGGCGGCGGCGG
>MY935944.1 Sequence 42 from patent US 11278572
GGTCATGGGTTA
>MY930036.1 Sequence 14 from patent US 11275088
TAGAAGGTTGGC
>MY930035.1 Sequence 13 from patent US 11275088
GAGCATACTTTG
>MY930020.1 Sequence 26 from patent US 11275081
TCGCGTCATATC
>MY930019.1 Sequence 25 from patent US 11275081
AGCGCAGTATAG
>MY929997.1 Sequence 3 from patent US 11275081
ATATATGTAAGG
>MY928551.1 Sequence 33 from patent US 11274348
GTGCAACTCATC
>MY928550.1 Sequence 32 from patent US 11274348
GTGCAACTCATC
>MY928549.1 Sequence 31 from patent US 11274348
GTGCAACTCATC
>MY928548.1 Sequence 30 from patent US 11274348
GTGCAGCTCATC
>MY928547.1 Sequence 29 from patent US 11274348
GTGCAGCTCATC
>MY928546.1 Sequence 28 from patent US 11274348
GTGCAGCTCATC
>MY917811.1 Sequence 17 from patent US 11274333
GTGTCGCCCTTA
>MY917810.1 Sequence 16 from patent US 11274333
TGTCGCCCTTAT
>MY917809.1 Sequence 15 from patent US 11274333
TCGCCCTTATTC
>MY917808.1 Sequence 14 from patent US 11274333
GCCCTTATTCCC
>MY917063.1 Sequence 679 from patent US 11274318
GTTTTAGAGCTA
>MY915530.1 Sequence 20 from patent US 11274304
AGCAAAAGCAGG
>MY915407.1 Sequence 39 from patent US 11274302
GCTGCGTGATGA
>MY915281.1 Sequence 36 from patent US 11274299
GCCGCCGCCGCC
>MY915280.1 Sequence 35 from patent US 11274299
GAAGAAGAAGAA
>MY915267.1 Sequence 22 from patent US 11274299
CCTGCCTGCCTG
>MY915266.1 Sequence 21 from patent US 11274299
CGGCGGCGGCGG
>MY915265.1 Sequence 20 from patent US 11274299
CTGCTGCTGCTG
>MY915264.1 Sequence 19 from patent US 11274299
GCGGCGGCGGCG
>MY915263.1 Sequence 18 from patent US 11274299
CAGCAGCAGCAG
>MY915208.1 Sequence 111 from patent US 11274294
AGACAAACCACA
>MY915207.1 Sequence 110 from patent US 11274294
CCGGATGCTCCT
>MY915206.1 Sequence 109 from patent US 11274294
CCCAGAAGTAAA
>MY915205.1 Sequence 108 from patent US 11274294
ATCAAGATTCTC
>MY915180.1 Sequence 23 from patent US 11274294
GCGCTCGAGTCC
>MY915179.1 Sequence 21 from patent US 11274294
GCGCTGGAGAGC
>MY914066.1 Sequence 13 from patent US 11273442
TTTTTTTTTTTT
>MY914000.1 Sequence 20 from patent US 11273214
AAATATAAAAAA
>MY913999.1 Sequence 19 from patent US 11273214
AATTATAAAAAA
>MY913997.1 Sequence 17 from patent US 11273214
AAATAAGAAAAA
>MY913996.1 Sequence 16 from patent US 11273214
AAATAAGAAAAA
>MY913991.1 Sequence 11 from patent US 11273214
AGGATTAAAGAC
>MY913385.1 Sequence 175 from patent US 11268159
GGAAAATTAATC
>MY913383.1 Sequence 173 from patent US 11268159
GAATWATGAAAG
>MY911717.1 Sequence 19 from patent US 11268144
AATCCCAATCCC
>MY910861.1 Sequence 4 from patent US 11268115
ATCGGATCCATT
>MY910254.1 Sequence 22 from patent US 11268098
TGCATCGATGCA
>MY909168.1 Sequence 18 from patent US 11268093
AAGAAGAAGAAG
>MY909157.1 Sequence 7 from patent US 11268093
CAGCAGCAGCAG
>MY908773.1 Sequence 8 from patent US 11268087
TTTTTTTTTTTT
>MY906364.1 Sequence 38 from patent US 11268086
AAGGCTAGTCCG
>MY905668.1 Sequence 23 from patent US 11268075
TTCTTAGCGTTT
>MY901734.1 Sequence 9 from patent US 11266672
GTCACGGCACCA
>MY901474.1 Sequence 1079 from patent US 11266655
RSCGGAAATRCM
>MY901464.1 Sequence 1069 from patent US 11266655
RGGTGYTAATWR
>MY901460.1 Sequence 1065 from patent US 11266655
RCCGGAWGTKKW
>MY901459.1 Sequence 1064 from patent US 11266655
RCCGGAWGTKKN
>MY901458.1 Sequence 1063 from patent US 11266655
RCCGGAWGTKKN
>MY901342.1 Sequence 947 from patent US 11266655
RSCGGAAATRCC
>MY901331.1 Sequence 936 from patent US 11266655
RCCGGAAATRCC
>MY901317.1 Sequence 922 from patent US 11266655
NNATGAYGCAAT
>MY901306.1 Sequence 911 from patent US 11266655
SGCGCTAATTKN
>MY901296.1 Sequence 901 from patent US 11266655
RSCGGATGTTKW
>MY901295.1 Sequence 900 from patent US 11266655
RSCGGATGTTGN
>MY901294.1 Sequence 899 from patent US 11266655
RSCGGATGTKKN
>MY901284.1 Sequence 889 from patent US 11266655
RGGTGTTAATKN
>MY901283.1 Sequence 888 from patent US 11266655
RGAATGCGGATN
>MY901278.1 Sequence 883 from patent US 11266655
RCCGGAAATRSY
>MY901276.1 Sequence 881 from patent US 11266655
NTGCCGGAAGTN
>MY901268.1 Sequence 873 from patent US 11266655
NGCCACGCAAYN
>MY901259.1 Sequence 864 from patent US 11266655
NTCGTAAAATGC
>MY901257.1 Sequence 862 from patent US 11266655
NNCGTAAAATTA
>MY901208.1 Sequence 813 from patent US 11266655
TMACACCYAATA
>MY901183.1 Sequence 788 from patent US 11266655
TNRCACCGGAWN
>MY901176.1 Sequence 781 from patent US 11266655
TGACASTAATKR
>MY901160.1 Sequence 765 from patent US 11266655
AGGTGNTAATTR
>MY901159.1 Sequence 764 from patent US 11266655
AGGTGNTAATKW
>MY901158.1 Sequence 763 from patent US 11266655
AGGTGNTAATKR
>MY901154.1 Sequence 759 from patent US 11266655
TMACACCGGAAG
>MY901123.1 Sequence 728 from patent US 11266655
GAAAACCGAAAN
>MY901121.1 Sequence 726 from patent US 11266655
AGGTGTTGACAN
>MY901120.1 Sequence 725 from patent US 11266655
AGGTGTTAATKN
>MY901119.1 Sequence 724 from patent US 11266655
ACCGGAAATGAN
>MY901117.1 Sequence 722 from patent US 11266655
TAAACAGGATTA
>MY901103.1 Sequence 708 from patent US 11266655
WTRMATATKYAW
>MY901102.1 Sequence 707 from patent US 11266655
WTRMATATKYAW
>MY901101.1 Sequence 706 from patent US 11266655
WTRMATATKYAW
>MY901100.1 Sequence 705 from patent US 11266655
WTGMATAAWTNA
>MY901099.1 Sequence 704 from patent US 11266655
WTGMATAAWTNA
>MY901087.1 Sequence 692 from patent US 11266655
WAWRTAAAYAWW
>MY901068.1 Sequence 673 from patent US 11266655
NMCMCGCCCMCN
>MY901054.1 Sequence 659 from patent US 11266655
NANCATATGNTN
>MY901051.1 Sequence 656 from patent US 11266655
WTATGCWAATKA
>MY901046.1 Sequence 651 from patent US 11266655
RGKGGGCGKGGC
>MY901035.1 Sequence 640 from patent US 11266655
WTATGCWAATNW
>MY901032.1 Sequence 637 from patent US 11266655
RCTAWAAATAGM
>MY901026.1 Sequence 631 from patent US 11266655
NWTATGCWAATN
>MY901025.1 Sequence 630 from patent US 11266655
NWACAYRACAWN
>MY901024.1 Sequence 629 from patent US 11266655
NWACAYRACAWN
>MY900992.1 Sequence 597 from patent US 11266655
NRTTACRTAAYN
>MY900991.1 Sequence 596 from patent US 11266655
NRTTACRTAAYN
>MY900966.1 Sequence 571 from patent US 11266655
NGTCGTWAAANN
>MY900961.1 Sequence 566 from patent US 11266655
NGCCNNNNGGCN
>MY900960.1 Sequence 565 from patent US 11266655
NGCCNNNNGGCN
>MY900959.1 Sequence 564 from patent US 11266655
NGCCNNNNGGCN
>MY900956.1 Sequence 561 from patent US 11266655
NCTAWAAATAGM
>MY900955.1 Sequence 560 from patent US 11266655
NCGACCACCNAN
>MY900943.1 Sequence 548 from patent US 11266655
NAMCCGGAAGTR
>MY900939.1 Sequence 544 from patent US 11266655
NAASATCAAAGN
>MY900938.1 Sequence 543 from patent US 11266655
NAANCGAAASYR
>MY900937.1 Sequence 542 from patent US 11266655
NAAGACGYCTTN
>MY900929.1 Sequence 534 from patent US 11266655
NAAACGATNNAN
>MY900928.1 Sequence 533 from patent US 11266655
MCCATATAWGGN
>MY900927.1 Sequence 532 from patent US 11266655
KCTAWAAATAGM
>MY900895.1 Sequence 500 from patent US 11266655
KGMCAGCGTGTC
>MY900893.1 Sequence 498 from patent US 11266655
YRATTGCAATYR
>MY900892.1 Sequence 497 from patent US 11266655
YGCGCATGCGCN
>MY900881.1 Sequence 486 from patent US 11266655
RGGGCACTAACY
>MY900880.1 Sequence 485 from patent US 11266655
RCGGACACAATR
>MY900877.1 Sequence 482 from patent US 11266655
NYYTGTTTACHN
>MY900874.1 Sequence 479 from patent US 11266655
NWAACCACADNN
>MY900868.1 Sequence 473 from patent US 11266655
NRTTACGTAAYN
>MY900867.1 Sequence 472 from patent US 11266655
NRTTACGTAAYN
>MY900824.1 Sequence 429 from patent US 11266655
NNNNNTGCTGAN
>MY900793.1 Sequence 398 from patent US 11266655
NGGCACGTGCCN
>MY900792.1 Sequence 397 from patent US 11266655
NGGCACGTGCCN
>MY900791.1 Sequence 396 from patent US 11266655
NGCGACCACCNN
>MY900784.1 Sequence 389 from patent US 11266655
NCGACCACCGAN
>MY900781.1 Sequence 386 from patent US 11266655
NCCGTTAACGGN
>MY900777.1 Sequence 382 from patent US 11266655
NATGCGGAAGTR
>MY900776.1 Sequence 381 from patent US 11266655
NATGACGTCAYN
>MY900763.1 Sequence 368 from patent US 11266655
NAAACCGGTTTN
>MY900755.1 Sequence 360 from patent US 11266655
WACCCGGAAGTA
>MY900754.1 Sequence 359 from patent US 11266655
VDTTTCCCGCCA
>MY900745.1 Sequence 350 from patent US 11266655
NTTTCCAGGAAA
>MY900744.1 Sequence 349 from patent US 11266655
NTGGGTGTGGCC
>MY900737.1 Sequence 342 from patent US 11266655
NACCCGGAAGTA
>MY900718.1 Sequence 323 from patent US 11266655
GRTGMTRGAGCC
>MY900690.1 Sequence 295 from patent US 11266655
GYCATCMATCAT
>MY900678.1 Sequence 283 from patent US 11266655
CGTRNAAARTGA
>MY900667.1 Sequence 272 from patent US 11266655
ACNGTTAAACNG
>MY900647.1 Sequence 252 from patent US 11266655
GAAASYGAAASY
>MY900638.1 Sequence 243 from patent US 11266655
AVYTATCGATAD
>MY900615.1 Sequence 220 from patent US 11266655
TGACAGSTGTCA
>MY900614.1 Sequence 219 from patent US 11266655
TGACAGSTGTCA
>MY900613.1 Sequence 218 from patent US 11266655
TGACAGSTGTCA
>MY900612.1 Sequence 217 from patent US 11266655
TGACAGSTGTCA
>MY900611.1 Sequence 216 from patent US 11266655
TGACAGSTGTCA
>MY900610.1 Sequence 215 from patent US 11266655
TGACAGSTGTCA
>MY900593.1 Sequence 198 from patent US 11266655
GSCTGTCACTCA
>MY900587.1 Sequence 192 from patent US 11266655
GCGACCACNCTG
>MY900578.1 Sequence 183 from patent US 11266655
ATTTCTNAGAAA
>MY900558.1 Sequence 163 from patent US 11266655
ACAATANCATTG
>MY900544.1 Sequence 149 from patent US 11266655
TGGGGAAGGGCM
>MY900522.1 Sequence 127 from patent US 11266655
AACCCGGAAGTR
>MY900521.1 Sequence 126 from patent US 11266655
AACCCGGAAGTR
>MY900520.1 Sequence 125 from patent US 11266655
AACCCGGAAGTN
>MY900515.1 Sequence 120 from patent US 11266655
TTTGGCGCCAAA
>MY900514.1 Sequence 119 from patent US 11266655
TTTGGCGCCAAA
>MY900513.1 Sequence 118 from patent US 11266655
TTTCCCGCCAAA
>MY900512.1 Sequence 117 from patent US 11266655
TTTCCCCACACG
>MY900511.1 Sequence 116 from patent US 11266655
TTTCCCCACACG
>MY900506.1 Sequence 111 from patent US 11266655
TGCCACGTGGCA
>MY900501.1 Sequence 106 from patent US 11266655
GTGCGCATGCGC
>MY900500.1 Sequence 105 from patent US 11266655
GTCCCCAGGGGA
>MY900492.1 Sequence 97 from patent US 11266655
GGTCCCTAGGGA
>MY900487.1 Sequence 92 from patent US 11266655
GGGGGTGTGTCC
>MY900486.1 Sequence 91 from patent US 11266655
GGCCATAAATCA
>MY900485.1 Sequence 90 from patent US 11266655
GCTTTTCCCACA
>MY900482.1 Sequence 87 from patent US 11266655
GATGACTCAGCA
>MY900481.1 Sequence 86 from patent US 11266655
GATGACGTCATC
>MY900479.1 Sequence 84 from patent US 11266655
GAAAGTGAAAGT
>MY900478.1 Sequence 83 from patent US 11266655
CTGCGCATGCGC
>MY900477.1 Sequence 82 from patent US 11266655
CGTGGGTGGTCC
>MY900472.1 Sequence 77 from patent US 11266655
CCATGCCGCCAT
>MY900470.1 Sequence 75 from patent US 11266655
CAAGATGGCGGC
>MY900468.1 Sequence 73 from patent US 11266655
ATGCCCTGAGGC
>MY900456.1 Sequence 61 from patent US 11266655
AGGTCTCTAACC
>MY900453.1 Sequence 58 from patent US 11266655
ACTTTCACTTTC
>MY900451.1 Sequence 56 from patent US 11266655
ACTACAATTCCC
>MY900449.1 Sequence 54 from patent US 11266655
ACCCTTGAACCC
>MY900444.1 Sequence 49 from patent US 11266655
AATGGCGCCAAA
>MY900443.1 Sequence 48 from patent US 11266655
AATGGCGCCAAA
>MY900206.1 Sequence 44 from patent US 11266129
TCCCAATGCGAG
>MY899686.1 Sequence 11 from patent US 11261487
TTTNTTNNTTTN
>MY899685.1 Sequence 10 from patent US 11261487
AAAAAAAAAAAA
>MY899634.1 Sequence 71 from patent US 11261483
ATTAGCTAAATG
>MY899633.1 Sequence 68 from patent US 11261483
AGATAGCATTTA
>MY899383.1 Sequence 27 from patent US 11261462
GTTCTACGTGGG
>MY899367.1 Sequence 11 from patent US 11261462
GGCGCCGCCACC
>MY899044.1 Sequence 13 from patent US 11261455
CCGCGGCCCGGG
>MY892241.1 Sequence 4490 from patent US 11260081
GGCGGTGGCGGT
>MY887572.1 Sequence 334 from patent US 11254989
CCGACGAGCCGA
>MY887536.1 Sequence 298 from patent US 11254989
CGTAGACACCTT
>MY887524.1 Sequence 286 from patent US 11254989
AGCTACCAGATT
>MY887516.1 Sequence 278 from patent US 11254989
CCAGACACCTCC
>MY887419.1 Sequence 181 from patent US 11254989
CAAGCAGAACCG
>MY887329.1 Sequence 91 from patent US 11254989
TGGAGACACATT
>MY887311.1 Sequence 73 from patent US 11254989
CCAGAGACAACT
>MY887298.1 Sequence 60 from patent US 11254989
ATCACATACAGC
>MY887275.1 Sequence 37 from patent US 11254989
AAGCCACTGTGT
>MY887272.1 Sequence 34 from patent US 11254989
AGTTTGTATGGA
>MY886727.1 Sequence 6 from patent US 11254975
TGGCCTGAGCAG
>MY882444.1 Sequence 898 from patent US 11254741
GACTTTGACTTG
>MY882424.1 Sequence 818 from patent US 11254741
AATCTAGAGATC
>MY882404.1 Sequence 778 from patent US 11254741
AATTTTGAGTTG
>MY882384.1 Sequence 738 from patent US 11254741
AATTTTGACTTG
>MY881762.1 Sequence 56 from patent US 11254731
GTGAGCAATAAT
>MY867219.1 Sequence 6 from patent US 11253601
CGATCATTCAAA
>MY867195.1 Sequence 136 from patent US 11253589
ATGTGTTGGAGT
>MY867191.1 Sequence 132 from patent US 11253589
ATGCCTAAGCGT
>MY867190.1 Sequence 131 from patent US 11253589
ATGCCTAAGCGT
>MY867189.1 Sequence 130 from patent US 11253589
ATGCCTAAGCGT
>MY867188.1 Sequence 129 from patent US 11253589
CCACACAGGCAT
>MY867186.1 Sequence 127 from patent US 11253589
GGGCGGGGGAGG
>MY867185.1 Sequence 126 from patent US 11253589
GGGCGGGGGAGG
>MY867184.1 Sequence 125 from patent US 11253589
GGGCGGGGGAGG
>MY867182.1 Sequence 123 from patent US 11253589
AAAGGTGGGCGG
>MY867181.1 Sequence 122 from patent US 11253589
AAAGGTGGGCGG
>MY867180.1 Sequence 121 from patent US 11253589
ACGCCCCAACAA
>MY867171.1 Sequence 112 from patent US 11253589
CCAACCAAGCAA
>MY867170.1 Sequence 111 from patent US 11253589
CCACCTACATAA
>MY867169.1 Sequence 110 from patent US 11253589
CCACCTACATAA
>MY867166.1 Sequence 107 from patent US 11253589
ACGCCTACTCTG
>MY867165.1 Sequence 106 from patent US 11253589
ACGCCTACTCTG
>MY867164.1 Sequence 105 from patent US 11253589
ACGCCTACTCTG
>MY867161.1 Sequence 102 from patent US 11253589
TTGCATGGGCTG
>MY867160.1 Sequence 101 from patent US 11253589
TTGCATGGGCTG
>MY867159.1 Sequence 100 from patent US 11253589
TTGCATGGGCTG
>MY867158.1 Sequence 99 from patent US 11253589
TTGCATGGGCTG
>MY867157.1 Sequence 98 from patent US 11253589
TTGCGTGGCCAG
>MY867156.1 Sequence 97 from patent US 11253589
TTGCGTGGCCAG
>MY867155.1 Sequence 96 from patent US 11253589
TTGCGTGGCCAG
>MY867154.1 Sequence 95 from patent US 11253589
TTGCGTGGCCAG
>MY867153.1 Sequence 94 from patent US 11253589
CCACCCCTGCAC
>MY867152.1 Sequence 93 from patent US 11253589
CCACCCCTGCAC
>MY867151.1 Sequence 92 from patent US 11253589
CTGCCCACACCT
>MY867149.1 Sequence 90 from patent US 11253589
CTTCCCACGCTC
>MY867146.1 Sequence 87 from patent US 11253589
TGGCGGGGGGGG
>MY867145.1 Sequence 86 from patent US 11253589
TGGCGGGGGGGG
>MY867143.1 Sequence 84 from patent US 11253589
CCTGCCACGCCA
>MY867142.1 Sequence 83 from patent US 11253589
CCTGCCACGCCA
>MY867135.1 Sequence 76 from patent US 11253589
TTACGTGGGTGC
>MY867134.1 Sequence 75 from patent US 11253589
TTACGTGGGTGC
>MY867133.1 Sequence 74 from patent US 11253589
TTACGTGGGTGC
>MY867130.1 Sequence 71 from patent US 11253589
GAGGGTGGGTGT
>MY867129.1 Sequence 70 from patent US 11253589
GAGGGTGGGTGT
>MY867128.1 Sequence 69 from patent US 11253589
GAGGGTGGGTGT
>MY867125.1 Sequence 66 from patent US 11253589
ACACACACTCAT
>MY867124.1 Sequence 65 from patent US 11253589
ACACACACTCAT
>MY867118.1 Sequence 59 from patent US 11253589
TTGTTGGGGCGG
>MY867117.1 Sequence 58 from patent US 11253589
CCTCCCTCTCAA
>MY867116.1 Sequence 57 from patent US 11253589
CCTCCCACACAC
>MY867115.1 Sequence 56 from patent US 11253589
CCTCCCACACAC
>MY867114.1 Sequence 55 from patent US 11253589
CCTCCCACACAC
>MY867113.1 Sequence 54 from patent US 11253589
CCTCCCACACAC
>MY867110.1 Sequence 51 from patent US 11253589
ACACTCCCGCAC
>MY867109.1 Sequence 50 from patent US 11253589
ACACTCCCGCAC
>MY867108.1 Sequence 49 from patent US 11253589
ACACCCACACTG
>MY867107.1 Sequence 48 from patent US 11253589
ACACCCACACTG
>MY867105.1 Sequence 46 from patent US 11253589
CCAACCACACAA
>MY867102.1 Sequence 43 from patent US 11253589
GTGCATAGGCTG
>MY867101.1 Sequence 42 from patent US 11253589
GTGCATAGGCTG
>MY867096.1 Sequence 37 from patent US 11253589
TTGCGTAGGCGG
>MY867095.1 Sequence 36 from patent US 11253589
TTGCGTAGGCGG
>MY867094.1 Sequence 35 from patent US 11253589
TTGCGTAGGCGG
>MY867093.1 Sequence 34 from patent US 11253589
TTGCGTAGGCGG
>MY867090.1 Sequence 31 from patent US 11253589
GCGCGTGGGCGG
>MY867089.1 Sequence 30 from patent US 11253589
GCGCGTGGGCGG
>MY867088.1 Sequence 29 from patent US 11253589
GCGCGTGGGCGG
>MY867087.1 Sequence 28 from patent US 11253589
GCGCGTGGGCGG
>MY867086.1 Sequence 27 from patent US 11253589
ACGCCCGCGCGT
>MY867085.1 Sequence 26 from patent US 11253589
ACGCCCGCGCGT
>MY867084.1 Sequence 25 from patent US 11253589
ACGCCCGCGCGT
>MY867083.1 Sequence 24 from patent US 11253589
ACGCCCGCGCGT
>MY867081.1 Sequence 22 from patent US 11253589
ACAGCCACGCGG
>MY867080.1 Sequence 21 from patent US 11253589
GAGCGTAGGCGG
>MY867079.1 Sequence 20 from patent US 11253589
GAGCGTAGGCGG
>MY867078.1 Sequence 19 from patent US 11253589
GAGCGTAGGCGG
>MY867077.1 Sequence 18 from patent US 11253589
GAGCGTAGGCGG
>MY867074.1 Sequence 15 from patent US 11253589
CCACCGCCGCCT
>MY867073.1 Sequence 14 from patent US 11253589
CCACCGCCGCCA
>MY867072.1 Sequence 13 from patent US 11253589
CAGCGCGGGCGG
>MY867071.1 Sequence 12 from patent US 11253589
CAGCGCGGGCGG
>MY867070.1 Sequence 11 from patent US 11253589
CAGCGCGGGCGG
>MY867069.1 Sequence 10 from patent US 11253589
CAGCGCGGGCGG
>MY866775.1 Sequence 19 from patent US 11253547
GGCCAGGCCGGC
>MY866756.1 Sequence 9 from patent US 11253536
GACGTCTCGAGT
>MY861638.1 Sequence 2 from patent US 11248228
GTCACTCTGCGT
>MY861431.1 Sequence 1075 from patent US 11248216
GTTTTAGAGCTA
>MY860978.1 Sequence 11 from patent US 11248060
CCATCTGTCTAT
>MY843044.1 Sequence 10 from patent US 11242554
TTTTTAATTTTT
>MY841985.1 Sequence 679 from patent US 11242543
GTTTTAGAGCTA
>MY835428.1 Sequence 130 from patent US 11242533
CGTAGAGCATCA
>MY819821.1 Sequence 38 from patent US 11242525
AAGGCTAGTCCG
>MY812477.1 Sequence 293 from patent US 11241485
GGAGGATCTGGA
>MY808858.1 Sequence 198 from patent US 11241025
GATCCTAATGGT
>MY808794.1 Sequence 124 from patent US 11241025
AGCGCCTTCGCC
>MY805433.1 Sequence 7 from patent US 11236377
CGTTAACATATT
>MY804146.1 Sequence 5 from patent US 11236343
TTTTGCAGTACT
>MY802849.1 Sequence 47 from patent US 11236329
AGCAGCAGCAGC
>MY802817.1 Sequence 64 from patent US 11236327
GTTTTAGAGCTA
>MY802685.1 Sequence 37 from patent US 11236313
AAGGCTAGTCCG
>MY801362.1 Sequence 143 from patent US 11235032
GGGGGGGGGGCG
>MY801361.1 Sequence 142 from patent US 11235032
GGGGGGGGTTCG
>MY801360.1 Sequence 141 from patent US 11235032
GGGGTTTTTTCG
>MY801359.1 Sequence 140 from patent US 11235032
GGTTTTTTTTCG
>MY801358.1 Sequence 139 from patent US 11235032
TTTTTTTTTTCG
>MY801357.1 Sequence 138 from patent US 11235032
GGGGGGTTTTCG
>MY801218.1 Sequence 85 from patent US 11235004
GACTTTGCATGT
>MY795422.1 Sequence 33 from patent US 11230708
TGGCCAGGAAGT
>MY795421.1 Sequence 29 from patent US 11230708
TGGCCAGGAAGT
>MY795420.1 Sequence 24 from patent US 11230708
CCCCCCCCCCCC
>MY795419.1 Sequence 23 from patent US 11230708
CCATAGGAAGCC
>MY795418.1 Sequence 21 from patent US 11230708
TGATAGGAAGTT
>MY795416.1 Sequence 14 from patent US 11230708
ACTTCCTGGCCA
>MY795415.1 Sequence 10 from patent US 11230708
ACTTCCTGGCCA
>MY795414.1 Sequence 6 from patent US 11230708
GGCTTCCTATGG
>MY795413.1 Sequence 4 from patent US 11230708
GGGGGGGGGGGG
>MY795412.1 Sequence 2 from patent US 11230708
AACTTCCTATCA
>MY794314.1 Sequence 23 from patent US 11230575
GGATCCGGTGGC
>MY794276.1 Sequence 35 from patent US 11230574
GGAAGTCCCGGG
>MY794275.1 Sequence 33 from patent US 11230574
CGAAAGGGATCA
>pdb|8D93|A Chain A, [2T7] Self-assembling tensegrity triangle with R3 symmetry at 2.96 A resolution, update and junction cut for entry 3GBI
GAGCAGCCTGTA
>PA565264.1 WO 2022255469-A/7: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
GCATTGGTATTC
>PA565263.1 WO 2022255469-A/6: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
GCATTGGTATTC
>PA565262.1 WO 2022255469-A/5: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
GCATTGGTATTC
>PA565261.1 WO 2022255469-A/4: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
GCATTGGTATTC
>PA565260.1 WO 2022255469-A/3: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
GCATTGGTATTC
>PA565259.1 WO 2022255469-A/2: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
GAATACCAATGC
>PA565258.1 WO 2022255469-A/1: PHOSOPHOROTHIOATE AND BORANOPHOSPHATE-INCLUDING CHIMERIC NUCLEIC ACID OLIGOMER AND METHOD FOR PRODUCING SAME
CAGTCAGTCAGT
>PA565253.1 WO 2022255411-A/11: Enhancement of innate immune response
CCCTTTCAGGCT
>PA564832.1 WO 2022260162-A/4: NASH preventive and/or therapeutic agents
AACAGCAATGCA
>PA564831.1 WO 2022260162-A/3: NASH preventive and/or therapeutic agents
AACTACAATGCA
>PA564830.1 WO 2022260162-A/2: NASH preventive and/or therapeutic agents
AACAGCAANGCA
>PA564829.1 WO 2022260162-A/1: NASH preventive and/or therapeutic agents
AACNACAANGCA
>pdb|7XP3|G Chain G, DNA complex form of ORESARA1(ANAC092) NAC Domain
AGTTACGTGTGG
>pdb|8CDN|D Chain D, Crystal structure of human Brachyury in complex with a single T box binding element DNA
AGGCTCACACCT
>pdb|8CDN|C Chain C, Crystal structure of human Brachyury in complex with a single T box binding element DNA
AGGTGTGAGCCT
>pdb|7YOJ|C Chain C, Structure of CasPi with guide RNA and target DNA
NGGGATGCCCAG
>pdb|7MWH|D Chain D, Crystal structure of BAZ2A with DNA
GCCTANATTCCG
>pdb|7MWH|C Chain C, Crystal structure of BAZ2A with DNA
CGGAATGTAGGC
>pdb|117D|A Chain A, CRYSTAL AND MOLECULAR STRUCTURE OF THE ALTERNATING DODECAMER D(GCGTACGTACGC) IN THE A-DNA FORM: COMPARISON WITH THE ISOMORPHOUS NON-ALTERNATING DODECAMER D(CCGTACGTACGG)
GCGTACGTACGC
>pdb|7U38|B Chain B, Pixantrone tethered DNA duplex
CGCNAATTNGCG
>pdb|7U38|A Chain A, Pixantrone tethered DNA duplex
CGCNAATTNGCG
>pdb|7ZQL|B Chain B, d(CGCGTTAACGCG)2 B-DODECAMER AT 3100 BARS (310 MPa)
CGCGAATTCGCG
>pdb|7ZQL|A Chain A, d(CGCGTTAACGCG)2 B-DODECAMER AT 3100 BARS (310 MPa)
CGCGAATTCGCG
>pdb|8E8K|T Chain T, Human DNA polymerase eta-DNA-rC-ended primer-dGMPNPP ternary mismatch complex with Mg2+
CATTGTGACGCT
>pdb|8E8J|T Chain T, Human DNA polymerase eta-DNA-rG-ended primer-dGMPNPP ternary mismatch complex with Mg2+
CATTCTGACGCT
>pdb|8E8H|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 300s
CATTATGACGCT
>pdb|8E8G|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 180s
CATTATGACGCT
>pdb|8E8F|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 120s
CATTATGACGCT
>pdb|8E8E|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 90s
CATTATGACGCT
>pdb|8E8D|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 60s
CATTATGACGCT
>pdb|8E8C|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 30s
CATTATGACGCT
>pdb|8E8B|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
CATTATGACGCT
>pdb|8E8A|T Chain T, Human DNA polymerase eta-DNA-dT-ended primer binary complex
CATTATGACGCT
>pdb|8E89|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer-binary complex
CATTATGACGCT
>pdb|8E88|T Chain T, Human DNA polymerase eta-DNA-rU-ended primer-dGMPNPP ternary mismatch complex with Mg2+
CATTATGACGCT
>pdb|8E87|T Chain T, Human DNA polymerase eta-DNA-rA-ended primer-dGMPNPP ternary mismatch complex with Mg2+
CATTTTGACGCT
>pdb|8E86|T Chain T, Human DNA polymerase eta-DNA-rC-ended primer-dGMPNPP ternary mismatch complex with Mn2+
CATTGTGACGCT
>pdb|8E85|T Chain T, Human DNA polymerase eta-DNA-rG-ended primer-dGMPNPP ternary mismatch complex with Mn2+
CATTCTGACGCT
>PA563379.1 WO 2022230987-A/11: Treatment or prevention of myopathy by using miR-33b inhibitor
AACAATACTACG
>PA563376.1 WO 2022230987-A/8: Treatment or prevention of myopathy by using miR-33b inhibitor
AACAGCAATGCA
>PA563375.1 WO 2022230987-A/7: Treatment or prevention of myopathy by using miR-33b inhibitor
AACTACAATGCA
>PA563373.1 WO 2022230987-A/5: Treatment or prevention of myopathy by using miR-33b inhibitor
AACAGCAATGCA
>pdb|8FDR|C Chain C, Structure of a dodecamer complex: 5'-CGCGAAAAGCCG-3-DB1476
CGCGTTTTCGCG
>pdb|8FDR|B Chain B, Structure of a dodecamer complex: 5'-CGCGAAAAGCCG-3-DB1476
CGCGAAAACGCG
>pdb|8FDQ|C Chain C, An AT-specific DNA 5-CGCAAATTTCGC-3' with benzimidazole (DB1476) complex
CGCAAATTTGCG
>pdb|8FDQ|B Chain B, An AT-specific DNA 5-CGCAAATTTCGC-3' with benzimidazole (DB1476) complex
CGCAAATTTGCG
>pdb|8FDP|C Chain C, The native structure of a dodecamer: 5'-CGCAAATTTGCG-3
CGCAAATTTGCG
>pdb|8FDP|B Chain B, The native structure of a dodecamer: 5'-CGCAAATTTGCG-3
CGCAAATTTGCG
>pdb|8F2Y|C Chain C, Structure of an alternating AT dodecamer: 5'-CGCGATATCGCG-3
CGCGATATCGCG
>pdb|8F2Y|B Chain B, Structure of an alternating AT dodecamer: 5'-CGCGATATCGCG-3
CGCGATATCGCG
>pdb|8F2W|C Chain C, Structure of a B-Form Dodecamer: 5'-CGCGAATTCGCG-3
CGCGAATTCGCG
>pdb|8F2W|B Chain B, Structure of a B-Form Dodecamer: 5'-CGCGAATTCGCG-3
CGCGAATTCGCG
>pdb|8F20|C Chain C, Structure of an A-tract B-DNA Dodecamer: 5'-CGCAAAAAAGCG-3
CGCTTTTTTGCG
>pdb|8F20|B Chain B, Structure of an A-tract B-DNA Dodecamer: 5'-CGCAAAAAAGCG-3
CGCAAAAAAGCG
>pdb|8F1V|C Chain C, A benzimidazole (DB1476) sequence-specific recognition of 5'-CGCAAAAAAGCG-3' in B-orientation
CGCTTTTTTGCG
>pdb|8F1V|B Chain B, A benzimidazole (DB1476) sequence-specific recognition of 5'-CGCAAAAAAGCG-3' in B-orientation
CGCAAAAAAGCG
>pdb|8F1S|C Chain C, A benzimidazole (DB1476) sequence-specific recognition of 5'-CGCAAAAAAGCG-3' in A-orientation
CGCTTTTTTGCG
>pdb|8F1S|B Chain B, A benzimidazole (DB1476) sequence-specific recognition of 5'-CGCAAAAAAGCG-3' in A-orientation
CGCAAAAAAGCG
>pdb|8EDB|C Chain C, 5'-CGCGAATTCGCG-3' and an AT-specific binder (DB1884) complex
CGCGAATTCGCG
>pdb|8EDB|B Chain B, 5'-CGCGAATTCGCG-3' and an AT-specific binder (DB1884) complex
CGCGAATTCGCG
>pdb|8EDA|C Chain C, An alternating AT dodecamer benzimidazole (DB1476) complex
CGCGATATCGCG
>pdb|8EDA|B Chain B, An alternating AT dodecamer benzimidazole (DB1476) complex
CGCGATATCGCG
>pdb|8ED6|C Chain C, 5'-CGCGAATTCGCG-3' and benzimidazole diamidine (DB1476) complex with ligand orientation II
CGCGAATTCGCG
>pdb|8ED6|B Chain B, 5'-CGCGAATTCGCG-3' and benzimidazole diamidine (DB1476) complex with ligand orientation II
CGCGAATTCGCG
>pdb|8EC1|C Chain C, 5'-CGCGAATTCGCG-3' and benzimidazole diamidine (DB1476) comlpex with ligand orientation I
CGCGAATTCGCG
>pdb|8EC1|B Chain B, 5'-CGCGAATTCGCG-3' and benzimidazole diamidine (DB1476) comlpex with ligand orientation I
CGCGAATTCGCG
>pdb|7XH3|B Chain B, Dimeric G-quadruplex DNA Formed in the Proximal Promoter of VEGFR-2
CCGGGTACCCGG
>pdb|7XH3|A Chain A, Dimeric G-quadruplex DNA Formed in the Proximal Promoter of VEGFR-2
CCGGGTACCCGG
>pdb|7YPB|I Chain I, Cryo-EM structure of Escherichia coli release complex of transcription termination (TTC-release)
GGCCTGCGACGA
>pdb|8DH5|O Chain O, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
AACTGCGGCGAT
>pdb|8DH5|K Chain K, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
AACTGCGGCGAT
>pdb|8DH5|G Chain G, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
AACTGCGGCGAT
>pdb|8DH5|C Chain C, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
AACTGCGGCGAT
>pdb|8DH4|O Chain O, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
AACTGCGGCGAT
>pdb|8DH4|K Chain K, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
AACTGCGGCGAT
>pdb|8DH4|G Chain G, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
AACTGCGGCGAT
>pdb|8DH4|C Chain C, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
AACTGCGGCGAT
>pdb|8DH3|O Chain O, T7 RNA polymerase elongation complex with unnatural base dPa
AACTGCGGCGAT
>pdb|8DH3|K Chain K, T7 RNA polymerase elongation complex with unnatural base dPa
AACTGCGGCGAT
>pdb|8DH3|G Chain G, T7 RNA polymerase elongation complex with unnatural base dPa
AACTGCGGCGAT
>pdb|8DH3|C Chain C, T7 RNA polymerase elongation complex with unnatural base dPa
AACTGCGGCGAT
>pdb|8DH2|N Chain N, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
AACTGCGGCGAT
>pdb|8DH2|K Chain K, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
AACTGCGGCGAT
>pdb|8DH2|G Chain G, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
AACTGCGGCGAT
>pdb|8DH2|C Chain C, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
AACTGCGGCGAT
>pdb|8DH1|N Chain N, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
AACTGCGGCGAT
>pdb|8DH1|K Chain K, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
AACTGCGGCGAT
>pdb|8DH1|G Chain G, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
AACTGCGGCGAT
>pdb|8DH1|C Chain C, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
AACTGCGGCGAT
>pdb|8DH0|O Chain O, T7 RNA polymerase elongation complex with unnatural base dDs
AACTGCGGCGAT
>pdb|8DH0|K Chain K, T7 RNA polymerase elongation complex with unnatural base dDs
AACTGCGGCGAT
>pdb|8DH0|G Chain G, T7 RNA polymerase elongation complex with unnatural base dDs
AACTGCGGCGAT
>pdb|8DH0|C Chain C, T7 RNA polymerase elongation complex with unnatural base dDs
AACTGCGGCGAT
>pdb|8CZQ|D Chain D, The crystal structure of MtbTOP1 in complex with both G- and T-segments
CTTCCGCTTGAC
>pdb|8CZQ|C Chain C, The crystal structure of MtbTOP1 in complex with both G- and T-segments
NTTCCGCTTGAC
>pdb|8CZQ|B Chain B, The crystal structure of MtbTOP1 in complex with both G- and T-segments
CTTCCGCTTGAC
>pdb|4RBO|F Chain F, Crystal structure of a Nanog homeobox (NANOG) from Homo sapiens at 3.30 A resolution
CTTGAATGGGCC
>pdb|4RBO|E Chain E, Crystal structure of a Nanog homeobox (NANOG) from Homo sapiens at 3.30 A resolution
GGCCCATTCAAG
>pdb|4RBO|C Chain C, Crystal structure of a Nanog homeobox (NANOG) from Homo sapiens at 3.30 A resolution
CTTGAATGGGCC
>pdb|4RBO|B Chain B, Crystal structure of a Nanog homeobox (NANOG) from Homo sapiens at 3.30 A resolution
GGCCCATTCAAG
>PA561650.1 WO 2022211075-A/4: Methods of producing Antibody Drug Conjugates and Enzymes therefor
ATCGAGGGAAGG
>PA561535.1 WO 2022220141-A/254: Method for detecting mutant SARS-CoV-2
AAGTTTAAAGGC
>PA561475.1 WO 2022220141-A/194: Method for detecting mutant SARS-CoV-2
CCCTTTTGGTGA
>PA561439.1 WO 2022220141-A/158: Method for detecting mutant SARS-CoV-2
CCGCCGACGAGA
>PA561435.1 WO 2022220141-A/154: Method for detecting mutant SARS-CoV-2
CCGATGAGAATT
>PA561433.1 WO 2022220141-A/152: Method for detecting mutant SARS-CoV-2
CGCCGATGAGAA
>PA561431.1 WO 2022220141-A/150: Method for detecting mutant SARS-CoV-2
CCGCCGAGGAGA
>PA561429.1 WO 2022220141-A/148: Method for detecting mutant SARS-CoV-2
CGCCGAGGAGAA
>PA561402.1 WO 2022220141-A/121: Method for detecting mutant SARS-CoV-2
ACTTTCCTTTAC
>PA561401.1 WO 2022220141-A/120: Method for detecting mutant SARS-CoV-2
TGTTACTTTCCT
>PA561322.1 WO 2022220141-A/41: Method for detecting mutant SARS-CoV-2
ATGGTGTTGAAG
>PA561316.1 WO 2022220141-A/35: Method for detecting mutant SARS-CoV-2
AACCCACTTATG
>PA559582.1 JP 2022154093-A/6: Method for detecting SNP
GAGCAGTGTCCT
>PE007257.1 KR 1020220084437-A/23: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
ATTCACTTTCAT
>PE007256.1 KR 1020220084437-A/22: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
TTCACTTTCATA
>PE007255.1 KR 1020220084437-A/21: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
TCACTTTCATAA
>PE007253.1 KR 1020220084437-A/19: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
CACTTTCATAAT
>PE007251.1 KR 1020220084437-A/17: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
ACTTTCATAATG
>PE007249.1 KR 1020220084437-A/15: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
CTTTCATAATGC
>PE007247.1 KR 1020220084437-A/13: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
TTTCATAATGCT
>PE007245.1 KR 1020220084437-A/11: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
TTCATAATGCTG
>PE007243.1 KR 1020220084437-A/9: COMPOSITION AND METHODS FOR MODULATING OF SMN2 SPLICING IN A SUBJECT
TCATAATGCTGG
>PE002109.1 KR 1020220075240-A/837: MASSIVELY PARALLEL SINGLE CELL ANALYSIS
AGCATTACCGAC
>PE001258.1 KR 1020220070579-A/64: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
ACACTGCTCAGC
>PE001257.1 KR 1020220070579-A/63: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
AGGAAGCTGCTG
>pdb|7QUA|A Chain A, Duplex RNA containing Xanthosine-Cytosine base pairs
CGCGNATTAGCG
>pdb|8A4I|D Chain D, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|C Chain C, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|H Chain H, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|G Chain G, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|F Chain F, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|E Chain E, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|B Chain B, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>pdb|8A4I|A Chain A, Crystal structure of SALL4 zinc finger cluster 4 with AT-rich DNA
GATATTAATATC
>OF490621.1 KR 1020220070324-A/288: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ATACTTACCTGG
>OF490602.1 KR 1020220070324-A/269: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
GCTACCTATATG
>OF490588.1 KR 1020220070324-A/255: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACCCACTCGCCA
>OF490585.1 KR 1020220070324-A/252: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ATACTTACCTGG
>OF490572.1 KR 1020220070324-A/239: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
GCTACCTATATG
>OF490535.1 KR 1020220070324-A/202: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ATACTTACCTGG
>OF490528.1 KR 1020220070324-A/195: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACCCACTCGCCA
>OF490527.1 KR 1020220070324-A/194: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACCCACTCGCCA
>OF490634.1 KR 1020220070324-A/301: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACCCACTCGCCA
>OF403899.1 KR 1020220024160-A/20: COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA
GTCATACACGGC
>OF403885.1 KR 1020220024160-A/6: COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA
TCATACACGGCT
>OF481533.1 KR 1020220053048-A/35: Antisense nucleic acids
CCTGGAGTTCCT
>OF481532.1 KR 1020220053048-A/34: Antisense nucleic acids
GTTTGCCGCTGC
>OF439623.1 KR 1020220024527-A/35: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
AGGGGATTTCCC
>OF439617.1 KR 1020220024527-A/29: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
TATGCAAATGAG
>OF439616.1 KR 1020220024527-A/28: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
GCGGCAGCTGCT
>OF439610.1 KR 1020220024527-A/22: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
GATGAGTCATCC
>OF439608.1 KR 1020220024527-A/20: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
GGATGAGTCATC
>OF439164.1 KR 1020220044266-A/5634: CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
GGATCCAGCGGC
>OF439160.1 KR 1020220044266-A/3626: CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
GCTAGCTTCGAA
>OF439139.1 KR 1020220044266-A/3556: CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
GGTGGATCCGGA
>OF439138.1 KR 1020220044266-A/3555: CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
GGAGGATCTGGA
>OF439108.1 KR 1020220044266-A/3461: CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
AGAACGAAGAGA
>OF479764.1 KR 1020220048049-A/7: METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATIONS AND METHODS OF USE
AAGGCTAGTCCG
>OF437768.1 KR 1020220008383-A/428: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGGTGTGGGC
>OF437767.1 KR 1020220008383-A/427: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCCACACCAAC
>OF437766.1 KR 1020220008383-A/426: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGGTGTGGGCC
>OF437765.1 KR 1020220008383-A/425: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCCACACCAA
>OF437764.1 KR 1020220008383-A/424: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGTGTGGGCCT
>OF437763.1 KR 1020220008383-A/423: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGCCCACACCA
>OF437762.1 KR 1020220008383-A/422: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGTGGGCCTC
>OF437761.1 KR 1020220008383-A/421: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGGCCCACACC
>OF437760.1 KR 1020220008383-A/420: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGTGGGCCTCC
>OF437759.1 KR 1020220008383-A/419: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAGGCCCACAC
>OF437758.1 KR 1020220008383-A/418: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTGGGCCTCCA
>OF437757.1 KR 1020220008383-A/417: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGAGGCCCACA
>OF437756.1 KR 1020220008383-A/416: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGGGCCTCCAC
>OF437755.1 KR 1020220008383-A/415: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGGAGGCCCAC
>OF437754.1 KR 1020220008383-A/414: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGGCCTCCACC
>OF437753.1 KR 1020220008383-A/413: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGGAGGCCCA
>OF437752.1 KR 1020220008383-A/412: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGGCCTCCACCA
>OF437751.1 KR 1020220008383-A/411: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGTGGAGGCCC
>OF437750.1 KR 1020220008383-A/410: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCTCCACCAG
>OF437749.1 KR 1020220008383-A/409: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGGTGGAGGCC
>OF437748.1 KR 1020220008383-A/408: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCTCCACCAGC
>OF437747.1 KR 1020220008383-A/407: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTGGTGGAGGC
>OF437746.1 KR 1020220008383-A/406: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTCCACCAGCT
>OF437745.1 KR 1020220008383-A/405: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCTGGTGGAGG
>OF437744.1 KR 1020220008383-A/404: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCATCCAGAAGC
>OF437743.1 KR 1020220008383-A/403: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTTCTGGATGG
>OF437742.1 KR 1020220008383-A/402: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CATCCAGAAGCC
>OF437741.1 KR 1020220008383-A/401: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCTTCTGGATG
>OF437740.1 KR 1020220008383-A/400: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATCCAGAAGCCA
>OF437739.1 KR 1020220008383-A/399: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGCTTCTGGAT
>OF437738.1 KR 1020220008383-A/398: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCCAGAAGCCAA
>OF437737.1 KR 1020220008383-A/397: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGGCTTCTGGA
>OF437736.1 KR 1020220008383-A/396: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAGAAGCCAAA
>OF437735.1 KR 1020220008383-A/395: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTTGGCTTCTGG
>OF437734.1 KR 1020220008383-A/394: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGAAGCCAAAC
>OF437733.1 KR 1020220008383-A/393: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTTGGCTTCTG
>OF437732.1 KR 1020220008383-A/392: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAGCCAAACT
>OF437731.1 KR 1020220008383-A/391: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTTTGGCTTCT
>OF437730.1 KR 1020220008383-A/390: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGCCAAACTG
>OF437729.1 KR 1020220008383-A/389: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTTTGGCTTC
>OF437728.1 KR 1020220008383-A/388: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGCCAAACTGG
>OF437727.1 KR 1020220008383-A/387: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAGTTTGGCTT
>OF437726.1 KR 1020220008383-A/386: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCCAAACTGGC
>OF437725.1 KR 1020220008383-A/385: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCAGTTTGGCT
>OF437724.1 KR 1020220008383-A/384: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCAAACTGGCC
>OF437723.1 KR 1020220008383-A/383: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCAGTTTGGC
>OF437722.1 KR 1020220008383-A/382: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAAACTGGCCA
>OF437721.1 KR 1020220008383-A/381: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGCCAGTTTGG
>OF437720.1 KR 1020220008383-A/380: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAAACTGGCCAC
>OF437719.1 KR 1020220008383-A/379: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGGCCAGTTTG
>OF437718.1 KR 1020220008383-A/378: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAACTGGCCACC
>OF437717.1 KR 1020220008383-A/377: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGGCCAGTTT
>OF437716.1 KR 1020220008383-A/376: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AACTGGCCACCC
>OF437715.1 KR 1020220008383-A/375: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGGTGGCCAGTT
>OF437714.1 KR 1020220008383-A/374: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACTGGCCACCCA
>OF437713.1 KR 1020220008383-A/373: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGGTGGCCAGT
>OF437712.1 KR 1020220008383-A/372: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTTCCTGCTCA
>OF437711.1 KR 1020220008383-A/371: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGAGCAGGAAGG
>OF437710.1 KR 1020220008383-A/370: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTTCCTGCTCAG
>OF437709.1 KR 1020220008383-A/369: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGAGCAGGAAG
>OF437708.1 KR 1020220008383-A/368: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTCCTGCTCAGG
>OF437707.1 KR 1020220008383-A/367: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTGAGCAGGAA
>OF437706.1 KR 1020220008383-A/366: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCCTGCTCAGGG
>OF437705.1 KR 1020220008383-A/365: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCCTGAGCAGGA
>OF437704.1 KR 1020220008383-A/364: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTGCTCAGGGT
>OF437703.1 KR 1020220008383-A/363: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACCCTGAGCAGG
>OF437702.1 KR 1020220008383-A/362: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGCTCAGGGTG
>OF437701.1 KR 1020220008383-A/361: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CACCCTGAGCAG
>OF437700.1 KR 1020220008383-A/360: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCTCAGGGTGA
>OF437699.1 KR 1020220008383-A/359: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCACCCTGAGCA
>OF437698.1 KR 1020220008383-A/358: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTCAGGGTGAT
>OF437697.1 KR 1020220008383-A/357: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATCACCCTGAGC
>OF437696.1 KR 1020220008383-A/356: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTCAGGGTGATA
>OF437695.1 KR 1020220008383-A/355: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TATCACCCTGAG
>OF437694.1 KR 1020220008383-A/354: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCAGGGTGATAT
>OF437693.1 KR 1020220008383-A/353: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATATCACCCTGA
>OF437692.1 KR 1020220008383-A/352: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCAGTCAGCCA
>OF437691.1 KR 1020220008383-A/351: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGCTGACTGGC
>OF437690.1 KR 1020220008383-A/350: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAGTCAGCCAT
>OF437689.1 KR 1020220008383-A/349: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATGGCTGACTGG
>OF437688.1 KR 1020220008383-A/348: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTCAGCCATG
>OF437687.1 KR 1020220008383-A/347: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CATGGCTGACTG
>OF437686.1 KR 1020220008383-A/346: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTCAGCCATGG
>OF437685.1 KR 1020220008383-A/345: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCATGGCTGACT
>OF437684.1 KR 1020220008383-A/344: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTCAGCCATGGA
>OF437683.1 KR 1020220008383-A/343: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCCATGGCTGAC
>OF437682.1 KR 1020220008383-A/342: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCAGCCATGGAG
>OF437681.1 KR 1020220008383-A/341: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTCCATGGCTGA
>OF437680.1 KR 1020220008383-A/340: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGCCATGGAGA
>OF437679.1 KR 1020220008383-A/339: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCTCCATGGCTG
>OF437678.1 KR 1020220008383-A/338: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGTTGCAGTAT
>OF437677.1 KR 1020220008383-A/337: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATACTGCAACAA
>OF437676.1 KR 1020220008383-A/336: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTTGCAGTATT
>OF437675.1 KR 1020220008383-A/335: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AATACTGCAACA
>OF437674.1 KR 1020220008383-A/334: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGCAGTATTT
>OF437673.1 KR 1020220008383-A/333: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAATACTGCAAC
>OF437672.1 KR 1020220008383-A/332: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGCAGTATTTC
>OF437671.1 KR 1020220008383-A/331: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAATACTGCAA
>OF437670.1 KR 1020220008383-A/330: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCAGTATTTCT
>OF437669.1 KR 1020220008383-A/329: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAATACTGCA
>OF437668.1 KR 1020220008383-A/328: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCAGTATTTCTC
>OF437667.1 KR 1020220008383-A/327: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGAAATACTGC
>OF437666.1 KR 1020220008383-A/326: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTATTTCTCC
>OF437665.1 KR 1020220008383-A/325: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAGAAATACTG
>OF437664.1 KR 1020220008383-A/324: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGTCGTGTTGT
>OF437663.1 KR 1020220008383-A/323: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACAACACGACCT
>OF437662.1 KR 1020220008383-A/322: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTCGTGTTGTA
>OF437661.1 KR 1020220008383-A/321: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TACAACACGACC
>OF437660.1 KR 1020220008383-A/320: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTCGTGTTGTAG
>OF437659.1 KR 1020220008383-A/319: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTACAACACGAC
>OF437658.1 KR 1020220008383-A/318: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCGTGTTGTAGT
>OF437657.1 KR 1020220008383-A/317: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACTACAACACGA
>OF437656.1 KR 1020220008383-A/316: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CGTGTTGTAGTC
>OF437655.1 KR 1020220008383-A/315: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACTACAACACG
>OF437654.1 KR 1020220008383-A/314: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGTTGTAGTCA
>OF437653.1 KR 1020220008383-A/313: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGACTACAACAC
>OF437652.1 KR 1020220008383-A/312: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTTGTAGTCAC
>OF437651.1 KR 1020220008383-A/311: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGACTACAACA
>OF437650.1 KR 1020220008383-A/310: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGTAGTCACT
>OF437648.1 KR 1020220008383-A/308: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGTAGTCACTG
>OF437647.1 KR 1020220008383-A/307: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTGACTACAA
>OF437646.1 KR 1020220008383-A/306: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTAGTCACTGT
>OF437645.1 KR 1020220008383-A/305: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACAGTGACTACA
>OF437644.1 KR 1020220008383-A/304: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTAGTCACTGTA
>OF437643.1 KR 1020220008383-A/303: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TACAGTGACTAC
>OF437642.1 KR 1020220008383-A/302: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TAGTCACTGTAG
>OF437641.1 KR 1020220008383-A/301: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTACAGTGACTA
>OF437640.1 KR 1020220008383-A/300: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGGAAGTGCCT
>OF437639.1 KR 1020220008383-A/299: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGCACTTCCTT
>OF437638.1 KR 1020220008383-A/298: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGAAGTGCCTT
>OF437637.1 KR 1020220008383-A/297: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGGCACTTCCT
>OF437636.1 KR 1020220008383-A/296: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAAGTGCCTTC
>OF437635.1 KR 1020220008383-A/295: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGGCACTTCC
>OF437634.1 KR 1020220008383-A/294: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGTGCCTTCT
>OF437633.1 KR 1020220008383-A/293: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAGGCACTTC
>OF437632.1 KR 1020220008383-A/292: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGTGCCTTCTC
>OF437631.1 KR 1020220008383-A/291: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGAAGGCACTT
>OF437630.1 KR 1020220008383-A/290: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTGCCTTCTCT
>OF437629.1 KR 1020220008383-A/289: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAGAAGGCACT
>OF437628.1 KR 1020220008383-A/288: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGCCTTCTCTG
>OF437627.1 KR 1020220008383-A/287: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGAGAAGGCAC
>OF437626.1 KR 1020220008383-A/286: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCCTTCTCTGT
>OF437625.1 KR 1020220008383-A/285: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACAGAGAAGGCA
>OF437624.1 KR 1020220008383-A/284: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCTTCTCTGTC
>OF437623.1 KR 1020220008383-A/283: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACAGAGAAGGC
>OF437622.1 KR 1020220008383-A/282: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTTCTCTGTCA
>OF437621.1 KR 1020220008383-A/281: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGACAGAGAAGG
>OF437620.1 KR 1020220008383-A/280: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTTCTCTGTCAT
>OF437619.1 KR 1020220008383-A/279: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATGACAGAGAAG
>OF437618.1 KR 1020220008383-A/278: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTCTCTGTCATG
>OF437617.1 KR 1020220008383-A/277: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CATGACAGAGAA
>OF437616.1 KR 1020220008383-A/276: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCTCTGTCATGC
>OF437615.1 KR 1020220008383-A/275: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCATGACAGAGA
>OF437614.1 KR 1020220008383-A/274: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTCTGTCATGCC
>OF437613.1 KR 1020220008383-A/273: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCATGACAGAG
>OF437612.1 KR 1020220008383-A/272: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGATGTTGGTGG
>OF437611.1 KR 1020220008383-A/271: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCACCAACATCT
>OF437610.1 KR 1020220008383-A/270: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GATGTTGGTGGC
>OF437609.1 KR 1020220008383-A/269: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCACCAACATC
>OF437608.1 KR 1020220008383-A/268: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATGTTGGTGGCC
>OF437607.1 KR 1020220008383-A/267: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCACCAACAT
>OF437606.1 KR 1020220008383-A/266: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTTGGTGGCCT
>OF437605.1 KR 1020220008383-A/265: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGCCACCAACA
>OF437604.1 KR 1020220008383-A/264: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGGTGGCCTG
>OF437603.1 KR 1020220008383-A/263: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGGCCACCAAC
>OF437602.1 KR 1020220008383-A/262: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGGTGGCCTGC
>OF437601.1 KR 1020220008383-A/261: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCAGGCCACCAA
>OF437600.1 KR 1020220008383-A/260: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGTGGCCTGCA
>OF437599.1 KR 1020220008383-A/259: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCAGGCCACCA
>OF437598.1 KR 1020220008383-A/258: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGGCCTGCAG
>OF437597.1 KR 1020220008383-A/257: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGCAGGCCACC
>OF437596.1 KR 1020220008383-A/256: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGACGCTGACCT
>OF437595.1 KR 1020220008383-A/255: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGTCAGCGTCT
>OF437594.1 KR 1020220008383-A/254: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACGCTGACCTC
>OF437593.1 KR 1020220008383-A/253: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGGTCAGCGTC
>OF437592.1 KR 1020220008383-A/252: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACGCTGACCTCC
>OF437591.1 KR 1020220008383-A/251: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAGGTCAGCGT
>OF437590.1 KR 1020220008383-A/250: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CGCTGACCTCCC
>OF437589.1 KR 1020220008383-A/249: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGGAGGTCAGCG
>OF437588.1 KR 1020220008383-A/248: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTGACCTCCCA
>OF437587.1 KR 1020220008383-A/247: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGGAGGTCAGC
>OF437586.1 KR 1020220008383-A/246: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGACCTCCCAG
>OF437585.1 KR 1020220008383-A/245: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGGGAGGTCAG
>OF437584.1 KR 1020220008383-A/244: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGACCTCCCAGC
>OF437583.1 KR 1020220008383-A/243: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTGGGAGGTCA
>OF437582.1 KR 1020220008383-A/242: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACCTCCCAGCT
>OF437581.1 KR 1020220008383-A/241: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCTGGGAGGTC
>OF437580.1 KR 1020220008383-A/240: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACCTCCCAGCTC
>OF437579.1 KR 1020220008383-A/239: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGCTGGGAGGT
>OF437578.1 KR 1020220008383-A/238: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTCAGCAGGTAC
>OF437577.1 KR 1020220008383-A/237: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTACCTGCTGAA
>OF437576.1 KR 1020220008383-A/236: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCAGCAGGTACT
>OF437575.1 KR 1020220008383-A/235: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTACCTGCTGA
>OF437649.1 KR 1020220008383-A/309: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTGACTACAAC
>OF437574.1 KR 1020220008383-A/234: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGCAGGTACTT
>OF437573.1 KR 1020220008383-A/233: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGTACCTGCTG
>OF437572.1 KR 1020220008383-A/232: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCAGGTACTTC
>OF437571.1 KR 1020220008383-A/231: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGTACCTGCT
>OF437570.1 KR 1020220008383-A/230: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCAGGTACTTCT
>OF437569.1 KR 1020220008383-A/229: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAGTACCTGC
>OF437568.1 KR 1020220008383-A/228: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGGTACTTCTT
>OF437567.1 KR 1020220008383-A/227: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGAAGTACCTG
>OF437566.1 KR 1020220008383-A/226: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGTACTTCTTC
>OF437565.1 KR 1020220008383-A/225: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGAAGTACCT
>OF437564.1 KR 1020220008383-A/224: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTACTTCTTCA
>OF437563.1 KR 1020220008383-A/223: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGAAGAAGTACC
>OF391346.1 KR 1020220024100-A/6: IMPROVEMENTS IN OR RELATING TO NICKING ENZYMES
GGTGCGCGCGGT
>OF391195.1 KR 1020220032525-A/2: METHODS AND SYSTEMS FOR DETECTING RESIDUAL DISEASE
TATGGTCATCGA
>OF391194.1 KR 1020220032525-A/1: METHODS AND SYSTEMS FOR DETECTING RESIDUAL DISEASE
TATGGTCGTCGA
>OF391167.1 KR 1020220009445-A/15: ARRAY AND METHOD FOR DETECTING SPATIAL INFORMATION OF NUCLEIC ACIDS
CCTTGGCTCACA
>OF389924.1 KR 1020220007675-A/4: COMPOSITIONS AND METHODS OF ACETYLCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS
GGTGGCGGCTCT
>OF389389.1 KR 1020220023985-A/21: EFFICIENT PPR PROTEIN PRODUCTION METHOD AND USE THEREOF
GGTCTCACATAC
>OF472136.1 KR 1020220079551-A/51: TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS, A CDK4/6 INHIBITOR AND A FURTHER THERAPEUTICALLY ACTIVE AGENT
ATCGATTTTCCA
>OF472135.1 KR 1020220079551-A/50: TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS, A CDK4/6 INHIBITOR AND A FURTHER THERAPEUTICALLY ACTIVE AGENT
ACAACTCCATCT
>OF387582.1 KR 1020220032516-A/22: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
TATGGTCGATCG
>OF387581.1 KR 1020220032516-A/21: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
TATGGTCGTCGA
>OF387578.1 KR 1020220032516-A/18: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
TATATGGTCGTC
>OF387577.1 KR 1020220032516-A/17: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
TGGTCGTCGAGC
>OF387576.1 KR 1020220032516-A/16: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
TATGGTCATCGA
>OF387575.1 KR 1020220032516-A/15: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
TATGGTCGTCGA
>OF387560.1 KR 1020220031860-A/8: METHODS FOR DETECTING NUCLEIC ACID VARIANTS
TATGGTCGATCG
>OF387559.1 KR 1020220031860-A/7: METHODS FOR DETECTING NUCLEIC ACID VARIANTS
TATGGTCGTCGA
>OF387556.1 KR 1020220031860-A/4: METHODS FOR DETECTING NUCLEIC ACID VARIANTS
TATATGGTCGTC
>OF387555.1 KR 1020220031860-A/3: METHODS FOR DETECTING NUCLEIC ACID VARIANTS
TGGTCGTCGAGC
>OF387554.1 KR 1020220031860-A/2: METHODS FOR DETECTING NUCLEIC ACID VARIANTS
TATGGTCATCGA
>OF387553.1 KR 1020220031860-A/1: METHODS FOR DETECTING NUCLEIC ACID VARIANTS
TATGGTCGTCGA
>OF471714.1 KR 1020220051401-A/197: GENETICALLY ENGINEERED T CELLS HAVING IMPROVED PERSISTENCE IN CULTURE
CCAGTGGGTAAG
>OF471711.1 KR 1020220051401-A/194: GENETICALLY ENGINEERED T CELLS HAVING IMPROVED PERSISTENCE IN CULTURE
CCTATTGCTAAG
>OF471685.1 KR 1020220051401-A/168: GENETICALLY ENGINEERED T CELLS HAVING IMPROVED PERSISTENCE IN CULTURE
CACACTGGCTTC
>OF387174.1 KR 1020220002609-A/702: MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTS
GGACCTGGGGAC
>OF386221.1 KR 1020220004703-A/124: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
CGGGCCAAGCGG
>OF386215.1 KR 1020220004703-A/118: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
AGGGCTAAACGG
>OF386194.1 KR 1020220004703-A/97: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
CGGGCCAAGCGG
>OF386188.1 KR 1020220004703-A/91: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
AGGGCTAAACGG
>OF386167.1 KR 1020220004703-A/70: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
CGGGCCAAGCGG
>OF386161.1 KR 1020220004703-A/64: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
AGGGCTAAACGG
>OF386154.1 KR 1020220004703-A/57: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
AGAGCAAAGCGG
>OF386133.1 KR 1020220004703-A/36: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
CGGGCCAAGCGG
>OF386127.1 KR 1020220004703-A/30: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
AGGGCTAAACGG
>OF386105.1 KR 1020220004703-A/8: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
CGGGCCAAGCGG
>OF386040.1 KR 1020220027825-A/7: ANTI-EphA4 ANTIBODY
ACATCACTCCGT
>OF469688.1 KR 1020220049619-A/467: SYSTEM FOR REGULATING GENE EXPRESSION
ACCAGATCTGTG
>OF469649.1 KR 1020220049619-A/428: SYSTEM FOR REGULATING GENE EXPRESSION
CCGTTATACTTC
>OF469630.1 KR 1020220049619-A/409: SYSTEM FOR REGULATING GENE EXPRESSION
GCGTTCCATTGT
>OF469616.1 KR 1020220049619-A/395: SYSTEM FOR REGULATING GENE EXPRESSION
GCGTTTATACTT
>OF469614.1 KR 1020220049619-A/393: SYSTEM FOR REGULATING GENE EXPRESSION
GCGTTATACTTC
>OF469613.1 KR 1020220049619-A/392: SYSTEM FOR REGULATING GENE EXPRESSION
AAAGTAAGTGCA
>OF469507.1 KR 1020220049619-A/286: SYSTEM FOR REGULATING GENE EXPRESSION
GCTAAAGTACCT
>OF469484.1 KR 1020220049619-A/263: SYSTEM FOR REGULATING GENE EXPRESSION
CTCGTGCATTGG
>OF469467.1 KR 1020220049619-A/246: SYSTEM FOR REGULATING GENE EXPRESSION
TACTAATAAAGT
>OF469464.1 KR 1020220049619-A/243: SYSTEM FOR REGULATING GENE EXPRESSION
CCTAATAAAGTA
>OF469455.1 KR 1020220049619-A/234: SYSTEM FOR REGULATING GENE EXPRESSION
ACTTTGTTACAC
>OF469450.1 KR 1020220049619-A/229: SYSTEM FOR REGULATING GENE EXPRESSION
TTTGTTAAACAC
>OF469446.1 KR 1020220049619-A/225: SYSTEM FOR REGULATING GENE EXPRESSION
ACTTTGTTACAC
>OF469432.1 KR 1020220049619-A/211: SYSTEM FOR REGULATING GENE EXPRESSION
TACCTAATAAAG
>OF469420.1 KR 1020220049619-A/199: SYSTEM FOR REGULATING GENE EXPRESSION
CTCGTGAGGGTG
>OF469416.1 KR 1020220049619-A/195: SYSTEM FOR REGULATING GENE EXPRESSION
TACTTCCACGAG
>OF469408.1 KR 1020220049619-A/187: SYSTEM FOR REGULATING GENE EXPRESSION
TACTTCCACGAG
>OF469406.1 KR 1020220049619-A/185: SYSTEM FOR REGULATING GENE EXPRESSION
CTCGTGAGGGTG
>OF469394.1 KR 1020220049619-A/173: SYSTEM FOR REGULATING GENE EXPRESSION
CTTTCCACGAGA
>OF469381.1 KR 1020220049619-A/160: SYSTEM FOR REGULATING GENE EXPRESSION
CTCGTGTCGGGT
>OF469355.1 KR 1020220049619-A/134: SYSTEM FOR REGULATING GENE EXPRESSION
TTGGACAGCAGG
>OF469352.1 KR 1020220049619-A/131: SYSTEM FOR REGULATING GENE EXPRESSION
TTGGACAGCAGG
>OF469350.1 KR 1020220049619-A/129: SYSTEM FOR REGULATING GENE EXPRESSION
CCTGCTGGGTGT
>OF469346.1 KR 1020220049619-A/125: SYSTEM FOR REGULATING GENE EXPRESSION
TGGACAGCAGGA
>OF469331.1 KR 1020220049619-A/110: SYSTEM FOR REGULATING GENE EXPRESSION
TTTGTTGGTGTT
>OF469327.1 KR 1020220049619-A/106: SYSTEM FOR REGULATING GENE EXPRESSION
CTTTGTTGGTGT
>OF469323.1 KR 1020220049619-A/102: SYSTEM FOR REGULATING GENE EXPRESSION
TTTGGACAACAA
>OF469316.1 KR 1020220049619-A/95: SYSTEM FOR REGULATING GENE EXPRESSION
GTACCTAATAAA
>OF469224.1 KR 1020220049619-A/3: SYSTEM FOR REGULATING GENE EXPRESSION
CACGAGATCTGG
>OF467712.1 KR 1020220044611-A/38: CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
AAGGCTAGTCCG
>OF380788.1 KR 1020220004053-A/498: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GATCTTGACTTG
>OF379426.1 KR 1020220010471-A/26: ELECTROCHEMILUMINESCENT LABELED PROBES FOR USE IN IMMUNOASSAY METHODS, METHODS USING SUCH AND KITS COMPRISING SAME
AAGCGTCTTAAC
>OF379407.1 KR 1020220010471-A/7: ELECTROCHEMILUMINESCENT LABELED PROBES FOR USE IN IMMUNOASSAY METHODS, METHODS USING SUCH AND KITS COMPRISING SAME
ACATCGGTAGTT
>OF463950.1 KR 1020220038550-A/7: IMPROVED ASSAY METHODS
ACATCGGTAGTT
>OF376074.1 KR 1020220058461-A/28: Composition for targeting cancer cell comprising a strain expressing monomeric streptavidin and a biotinylated compound
AAAGAGGAGAAA
>OF375985.1 KR 1020220058460-A/28: A construct expressing monomeric streptavidin
AAAGAGGAGAAA
>OF459643.1 KR 1020220047319-A/202: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GANACTTACCTG
>OF459633.1 KR 1020220047319-A/192: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNNGCNCNA
>OF459613.1 KR 1020220047319-A/172: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
CCTGGATGGGAA
>OF459578.1 KR 1020220047319-A/137: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
NATACTTACCTG
>OF459577.1 KR 1020220047319-A/136: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
NNTACTTACCTG
>OF459575.1 KR 1020220047319-A/134: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GNTACTTACCTG
>OF459559.1 KR 1020220047319-A/118: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
CCTGGATGGGAA
>OF374819.1 KR 1020220031527-A/8: Method for detecting noxious substance of food
AAGCCATCAGTC
>OF374617.1 KR 1020220027785-A/7: Novel coronavirus recombinant spike protein, polynucleotide encoding the protein, vector comprising the polynucleotide, and vaccine for preventing or treating coronavirus infection comprising the vector
ACGATCCTCCGT
>OF374356.1 KR 1020220040983-A/14: Prime editing-based gene editing composition with improved editing efficiency and use thereof
ACCTCTTTCACT
>OF374355.1 KR 1020220040983-A/13: Prime editing-based gene editing composition with improved editing efficiency and use thereof
CCTATAAGAGAC
>OF373733.1 KR 1020220002156-A/10: Kit for screening for therapeutic agent for preventing or treating Corona-virus infection by using of esterase activity of Corona-19 virus spike protein and pharmaceutical composition comprising material selected therefrom
CACGATGAGCTC
>OF372818.1 KR 1020220047502-A/552: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
TTTTATTTTTTT
>OF372700.1 KR 1020220047502-A/412: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
NGNNNTGAAGGA
>OF372688.1 KR 1020220047502-A/400: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
TTCTCTTTCTTT
>OF372683.1 KR 1020220047502-A/395: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
TTTGTTTGTTTT
>OF372670.1 KR 1020220047502-A/382: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
BNNNNTGAAGGA
>OF372660.1 KR 1020220047502-A/372: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
NBNNNTGAAGGA
>OF372650.1 KR 1020220047502-A/362: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
NNBNNTGAAGGA
>OF372640.1 KR 1020220047502-A/352: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
NNNBNTGAAGGA
>OF372630.1 KR 1020220047502-A/342: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
NNNNBTGAAGGA
>OF372539.1 KR 1020220047502-A/251: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
TAAAGTGGAGAA
>OF372534.1 KR 1020220047502-A/246: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
CCGCTTAGGGTG
>OF372443.1 KR 1020220047502-A/155: An engineered guide RNA for the optimized CRISPR/Cas12f1(Cas14a1) system and use thereof
CAAATTCANNNN
>OF456482.1 KR 1020220028183-A/51: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
ATCTAATAAGCT
>OF456481.1 KR 1020220028183-A/50: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
AATCTAATAAGC
>OF456475.1 KR 1020220028183-A/44: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
TCTAATAAGCTA
>OF456468.1 KR 1020220028183-A/37: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
GTCTGATAAGCT
>OF456467.1 KR 1020220028183-A/36: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
AGTCTGATAAGC
>OF456453.1 KR 1020220028183-A/22: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
TCTGATAAGCTA
>OF370504.1 KR 1020220083156-A/20: GKN1 SPECIFIC ANTIBODY AND USE THEREOF
GCTAACACCAAC
>OF368904.1 KR 1020220073376-A/7: Composition containing Cel12A protein for decomposing cellulose and method for manufacturing the thereof
CATGACGAGCTT
>OF368769.1 KR 1020220071536-A/8: Method and Kits for Amplifying Target Nucleic Acid with High Specificity
GTCAAGGCACTC
>OF454240.1 KR 1020220035937-A/44: REGULATABLE EXPRESSION SYSTEMS
CGTACTAAAAGA
>OF454235.1 KR 1020220035937-A/19: REGULATABLE EXPRESSION SYSTEMS
CGCAACCGCCGC
>OF367878.1 KR 1020220047493-A/25: An engineered crRNA for CRISPR/Cas12a system
TTTCAATTTTTT
>OF367825.1 KR 1020220062841-A/2: Method and Kit for Identifying F18 encoding enterotoxigenic and shigatoxin-producing Escherichia coli in Pigs using PNA probe
AAACCGTGAACG
>OF367824.1 KR 1020220062841-A/1: Method and Kit for Identifying F18 encoding enterotoxigenic and shigatoxin-producing Escherichia coli in Pigs using PNA probe
ACAGCCGGTGCA
>OF367677.1 KR 1020220061480-A/2: Manufacturing method of circular nucleic acid template for producing high molecular weight protein using hydrogelated nucleic acid
ACCCTAACCCTA
>OF367676.1 KR 1020220061480-A/1: Manufacturing method of circular nucleic acid template for producing high molecular weight protein using hydrogelated nucleic acid
TAGGGTTAGGGT
>OF364856.1 KR 1020220031452-A/19: Method for simultaneous detection of foodborne pathogens using chip for multiplex detection
AGCTCTGTGGCG
>OF492608.1 KR 1020220082047-A/19: VECTOR FOR CANCER TREATMENT
CCCGCCGCCACC
>OF363877.1 KR 1020220025587-A/18: Helix 73-derived RNA molecules interacting with Erm protein and methods of use thereof
CCTATCCGTCGC
>OF363872.1 KR 1020220025587-A/13: Helix 73-derived RNA molecules interacting with Erm protein and methods of use thereof
AGGACGGAAAGA
>OF363871.1 KR 1020220025587-A/12: Helix 73-derived RNA molecules interacting with Erm protein and methods of use thereof
CCTATCCGTCGC
>OF363497.1 KR 1020220022260-A/9: Vaccine compositions comprising plant expressing recombinant Zika virus envelope proteins and preparation methods thereof
CACGATGAGCTC
>OF490874.1 KR 1020220070324-A/547: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ATACTTACCTGG
>OF450349.1 KR 1020220021019-A/2: COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
CTAGGGGGTTGC
>OF490672.1 KR 1020220070324-A/339: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
GCTACCTATATG
>OF490636.1 KR 1020220070324-A/303: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACCCACTCGCCA
>OF405951.1 KR 1020220035338-A/184: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
ACTAGTGCTTCC
>OF405950.1 KR 1020220035338-A/183: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
TTGACACGAATT
>OF405949.1 KR 1020220035338-A/182: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
TGATCACGAAGT
>OF362978.1 KR 1020220015211-A/1: antimicrobial composition against Floroquinolone antibiotic-resistant E. coli comprising novel peptide nucleic acid
TATAAACCGCCA
>pdb|8ASK|BBB Chain BBB, Crystal structure of d(GCCCACCACGGC)
NCCGTGGTGGGC
>pdb|8ASK|AAA Chain AAA, Crystal structure of d(GCCCACCACGGC)
NCCCACCACGGC
>pdb|7WM3|H Chain H, hnRNP A2/B1 RRMs in complex with single-stranded DNA
NTAGGGTTAGGG
>pdb|7WM3|G Chain G, hnRNP A2/B1 RRMs in complex with single-stranded DNA
NTAGGGTTAGGG
>pdb|7WM3|F Chain F, hnRNP A2/B1 RRMs in complex with single-stranded DNA
NTAGGGTTAGGG
>pdb|7WM3|E Chain E, hnRNP A2/B1 RRMs in complex with single-stranded DNA
NTAGGGTTAGGG
>pdb|7RQT|B Chain B, THE B-DNA DODECAMER With HIGH RESOLUTION
CGCGAATTCGCG
>pdb|7RQT|A Chain A, THE B-DNA DODECAMER With HIGH RESOLUTION
CGCGAATTCGCG
>pdb|6X5D|B Chain B, Structure of Dickerson-Drew Dodecamer with 2'-MeSe-ara-T modification
CGCGAATNCGCG
>pdb|6X5D|A Chain A, Structure of Dickerson-Drew Dodecamer with 2'-MeSe-ara-T modification
CGCGAATNCGCG
>PA557745.1 WO 2022191172-A/5: LINKER AND CARRIER FOR NUCLEIC ACID SOLID-PHASE SYNTHESIS
GGATGTTCTCGT
>PA556429.1 WO 2022186197-A/37: Solanaceae plant and solanaceae plant cells resistant to Begomovirus causing yellow leaf curling symptoms in tomato and method for producing such solanaceae plant
TGTGACCGGTAT
>PA555646.1 WO 2022185664-A/6: translation enhancer
GGGCCGAAAAGA
>PA555498.1 JP 2022134257-A/6: translation enhancer
GGGCCGAAAAGA
>pdb|8EAM|X Chain X, SsoMCM hexamer bound to Mg/ADP-BeFx and DNA. Class 2. Merged particles from datasets with 3 different DNA entities
NTTTTTTTTTTT
>pdb|8EAL|X Chain X, SsoMCM hexamer bound to Mg/ADP-BeFx and DNA. Class 1. Merged particles from datasets with 3 different DNA entities
NTTTTTTTTTTT
>pdb|8EAG|X Chain X, SsoMCM hexamer bound to Mg/ADP-BeFx and 12-mer oligo-dT. Class 2
NTTTTTTTTTTT
>pdb|8EAF|X Chain X, SsoMCM hexamer bound to Mg/ADP-BeFx and 12-mer oligo-dT. Class 1
NTTTTTTTTTTT
>pdb|6XU7|v Chain v, Drosophila melanogaster Testis polysome ribosome
NGGTGTGGCCCT
>pdb|1NH3|C Chain C, Human Topoisomerase I Ara-C Complex
NGAAAAANNNNT
>pdb|1LE9|H Chain H, Crystal structure of a NF-kB heterodimer bound to the Ig/HIV-kB siti
AAGGAAAGTCCC
>pdb|1LE9|G Chain G, Crystal structure of a NF-kB heterodimer bound to the Ig/HIV-kB siti
TGGGACTTTCCT
>pdb|1LE9|D Chain D, Crystal structure of a NF-kB heterodimer bound to the Ig/HIV-kB siti
AAGGAAAGTCCC
>pdb|1LE9|C Chain C, Crystal structure of a NF-kB heterodimer bound to the Ig/HIV-kB siti
TGGGACTTTCCT
>pdb|1LE5|H Chain H, Crystal structure of a NF-kB heterodimer bound to an IFNb-kB
AAGGAATTTCCC
>pdb|1LE5|G Chain G, Crystal structure of a NF-kB heterodimer bound to an IFNb-kB
TGGGAAATTCCT
>pdb|1LE5|D Chain D, Crystal structure of a NF-kB heterodimer bound to an IFNb-kB
AAGGAATTTCCC
>pdb|1LE5|C Chain C, Crystal structure of a NF-kB heterodimer bound to an IFNb-kB
TGGGAAATTCCT
>pdb|8AAD|A Chain A, Two carbons pendant pyridine derivative of the natural alkaloid Berberine as Human Telomeric G-quadruplex Binder
TAGGGTTAGGGT
>pdb|7ZUR|A Chain A, Four carbons pendant pyridine derivative of the natural alkaloid Berberine as Human Telomeric G-quadruplex Binder
TAGGGTTAGGGT
>pdb|7XIB|C Chain C, Cryo-EM structure of human DNMT1 (aa:351-1616) in complex with ubiquitinated H3 and hemimethylated DNA analog (CXXC-disordered form)
CCTTCNGTAAGT
>pdb|7XIB|B Chain B, Cryo-EM structure of human DNMT1 (aa:351-1616) in complex with ubiquitinated H3 and hemimethylated DNA analog (CXXC-disordered form)
ACTTANGGAAGG
>pdb|7XI9|C Chain C, Cryo-EM structure of human DNMT1 (aa:351-1616) in complex with ubiquitinated H3 and hemimethylated DNA analog (CXXC-ordered form)
CCTTCNGTAAGT
>pdb|7XI9|B Chain B, Cryo-EM structure of human DNMT1 (aa:351-1616) in complex with ubiquitinated H3 and hemimethylated DNA analog (CXXC-ordered form)
ACTTANGGAAGG
>PA554594.1 WO 2022176959-A/45: ANTI-PT217 TAU ANTIBODY
AGAATGGCCTAC
>PA554585.1 WO 2022176959-A/36: ANTI-PT217 TAU ANTIBODY
AGACTGTCTATC
>PA554562.1 WO 2022176959-A/13: ANTI-PT217 TAU ANTIBODY
AGAATGGCATAC
>PA554552.1 WO 2022176959-A/3: ANTI-PT217 TAU ANTIBODY
AGACTGTCCATC
>pdb|7Y3L|H Chain H, Structure of SALL3 ZFC4 bound with 12 bp AT-rich dsDNA
NGTAATATTTCC
>pdb|7Y3L|G Chain G, Structure of SALL3 ZFC4 bound with 12 bp AT-rich dsDNA
NGAAATATTACC
>pdb|7Y3I|H Chain H, Structure of DNA bound SALL4
NGTAATATTTCC
>pdb|7Y3I|G Chain G, Structure of DNA bound SALL4
NGAAATATTACC
>pdb|7Y3I|K Chain K, Structure of DNA bound SALL4
NGTAATATTTCC
>pdb|7Y3I|L Chain L, Structure of DNA bound SALL4
NGAAATATTACC
>pdb|8H2H|B Chain B, Cryo-EM structure of a Group II Intron Complexed with its Reverse Transcriptase
NACATCCATAAC
>pdb|7ZO1|D Chain D, SpCas9 bound to CD34 off-target9 DNA substrate
AATATGGTATTG
>pdb|7QR8|D Chain D, SpCas9 bound to PTPRC off-target1 DNA substrate
CCCCTGGTATTG
>pdb|7QR7|D Chain D, SpCas9 bound to AAVS1 off-target2 DNA substrate
GGTTTGGTATTG
>pdb|7QR5|D Chain D, SpCas9 bound to FANCF off-target6 DNA substrate
CTCCAGGTATTG
>pdb|7QR1|D Chain D, SpCas9 bound to TRAC off-target2 DNA substrate
TACATGGTATTG
>pdb|7QR0|D Chain D, SpCas9 bound to TRAC off-target1 DNA substrate
TACATGGTATTG
>pdb|7QQZ|D Chain D, SpCas9 bound to FANCF off-target7 DNA substrate
CACCAGGTATTG
>pdb|7QQX|D Chain D, SpCas9 bound to FANCF off-target5 DNA substrate
CACCAGGTATTG
>pdb|7QQW|D Chain D, SpCas9 bound to FANCF off-target4 DNA substrate
CACCAGGTATTG
>pdb|7QQV|D Chain D, SpCas9 bound to FANCF off-target3 DNA substrate
GACCCGGTATTG
>pdb|7QQU|D Chain D, SpCas9 bound to FANCF off-target2 DNA substrate
CACCAGGTATTG
>pdb|7QQT|D Chain D, SpCas9 bound to FANCF off-target1 DNA substrate
CACCAGGTATTG
>pdb|7QQS|D Chain D, SpCas9 bound to FANCF on-target DNA substrate
CACCTGGTATTG
>pdb|7QQR|D Chain D, SpCas9 bound to AAVS1 off-target5 DNA substrate
GGCCTGGTATTG
>pdb|7QQQ|D Chain D, SpCas9 bound to AAVS1 off-target4 DNA substrate
GGAATGGTATTG
>pdb|7QQP|D Chain D, SpCas9 bound to AAVS1 off-target3 DNA substrate
GGATAGGTATTG
>pdb|5WFS|x Chain x, 70S ribosome-EF-Tu H84A complex with GTP and near-cognate tRNA (Complex C4)
NCTATGCTCACG
>pdb|5WF0|x Chain x, 70S ribosome-EF-Tu H84A complex with GTP and near-cognate tRNA (Complex C2)
NCTATGCTCACG
>pdb|5WE4|x Chain x, 70S ribosome-EF-Tu wt complex with GppNHp
NCTATGTTCACG
>pdb|2EZG|C Chain C, SOLUTION STRUCTURE OF A COMPLEX OF THE THIRD DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, 35 STRUCTURES
GAGGAATTTCCC
>pdb|2EZG|B Chain B, SOLUTION STRUCTURE OF A COMPLEX OF THE THIRD DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, 35 STRUCTURES
GGGAAATTCCTC
>pdb|2EZE|C Chain C, SOLUTION STRUCTURE OF A COMPLEX OF THE SECOND DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, 35 STRUCTURES
GAGGAATTTCCC
>pdb|2EZE|B Chain B, SOLUTION STRUCTURE OF A COMPLEX OF THE SECOND DNA BINDING DOMAIN OF HUMAN HMG-I(Y) BOUND TO DNA DODECAMER CONTAINING THE PRDII SITE OF THE INTERFERON-BETA PROMOTER, NMR, 35 STRUCTURES
GGGAAATTCCTC
>pdb|6X5N|a Chain a, Crystal structure of a stabilized PAN ENE bimolecular triplex with a GC-clamped polyA tail, in complex with Fab-BL-3,6
NGCAAAAAAAAA
>pdb|6X5M|a Chain a, Crystal structure of a stabilized PAN ENE bimolecular triplex with a GC-clamped polyA tail, in complex with Fab-BL-3,6.
NGCAAAAAAAAA
>pdb|5WFK|x Chain x, 70S ribosome-EF-Tu H84A complex with GTP and near-cognate tRNA (Complex C3)
NCTATGCTCACG
>pdb|5WE6|x Chain x, 70S ribosome-EF-Tu H84A complex with GTP and cognate tRNA
NCTATGTTCACG
>pdb|5WDT|x Chain x, 70S ribosome-EF-Tu H84A complex with GppNHp
NCTATGTTCACG
>pdb|6X5N|A Chain A, Crystal structure of a stabilized PAN ENE bimolecular triplex with a GC-clamped polyA tail, in complex with Fab-BL-3,6
NGCAAAAAAAAA
>pdb|6X5M|A Chain A, Crystal structure of a stabilized PAN ENE bimolecular triplex with a GC-clamped polyA tail, in complex with Fab-BL-3,6.
NGCAAAAAAAAA
>pdb|7VP3|O Chain O, Structure of a transcription factor and DNA complex
TGGGGACCCACA
>pdb|7VP3|M Chain M, Structure of a transcription factor and DNA complex
ATGTGGGTCCCC
>pdb|7VP3|K Chain K, Structure of a transcription factor and DNA complex
ATGTGGGTCCCC
>pdb|7VP3|H Chain H, Structure of a transcription factor and DNA complex
TGGGGACCCACA
>pdb|7VP3|F Chain F, Structure of a transcription factor and DNA complex
ATGTGGGTCCCC
>pdb|7VP3|A Chain A, Structure of a transcription factor and DNA complex
TGGGGACCCACA
>pdb|7VP3|E Chain E, Structure of a transcription factor and DNA complex
ATGTGGGTCCCC
>pdb|7VP3|B Chain B, Structure of a transcription factor and DNA complex
TGGGGACCCACA
>pdb|8CU0|E Chain E, 12-mer DNA structure of ExBIM bound to RNaseH -modified DDD
CGGGCATGNCCG
>pdb|8CU0|D Chain D, 12-mer DNA structure of ExBIM bound to RNaseH -modified DDD
CGGGCATGNCCG
>pdb|8CTZ|E Chain E, 12-mer DNA structure of ExBIM & O6Me-G bound to RNase-H
CGCNAATTNGCG
>pdb|8CTZ|D Chain D, 12-mer DNA structure of ExBIM & O6Me-G bound to RNase-H
CGCNAATTNGCG
>pdb|8CTY|N Chain N, 12-mer DNA structure of ExBIM bound to RNase-H
CGCGAATTNGCG
>pdb|8CTY|M Chain M, 12-mer DNA structure of ExBIM bound to RNase-H
CGCGAATTNGCG
>pdb|8CTY|L Chain L, 12-mer DNA structure of ExBIM bound to RNase-H
CGCGAATTNGCG
>pdb|8CTY|K Chain K, 12-mer DNA structure of ExBIM bound to RNase-H
CGCGAATTNGCG
>pdb|8CTY|J Chain J, 12-mer DNA structure of ExBIM bound to RNase-H
CGCGAATTNGCG
>pdb|8CTY|I Chain I, 12-mer DNA structure of ExBIM bound to RNase-H
CGCGAATTNGCG
>PA552880.1 WO 2022154079-A/5: Method for introducing proteins into animal cells
AAACTGCAAAAG
>PA552879.1 WO 2022154079-A/4: Method for introducing proteins into animal cells
CTTTTGCAGTTT
>NM_001349604.1 Arabidopsis thaliana uncharacterized protein (AT5G40315), partial mRNA
ATGAAAAGTCAA
>NM_001349584.1 Arabidopsis thaliana uncharacterized protein (AT2G21105), partial mRNA
TTCAAAGATTGA
>pdb|7VP1|D Chain D, Structure of a transcription factor and DNA complex
TGGGGGACCACA
>pdb|7VP1|C Chain C, Structure of a transcription factor and DNA complex
ATGTGGTCCCCC
>pdb|7XKM|D Chain D, Crystal structure of DNA-Ag(I) rod comprising a one-dimensional array of 11 silver ions
CGCGCNCNCGCG
>pdb|7XKM|C Chain C, Crystal structure of DNA-Ag(I) rod comprising a one-dimensional array of 11 silver ions
CGCGCNCNCGCG
>pdb|7XKM|B Chain B, Crystal structure of DNA-Ag(I) rod comprising a one-dimensional array of 11 silver ions
CGCGCNCNCGCG
>pdb|7XKM|A Chain A, Crystal structure of DNA-Ag(I) rod comprising a one-dimensional array of 11 silver ions
CGCGCNCNCGCG
>pdb|7VKI|B Chain B, ESRP1 qRRM2 in complex with 12mer-RNA
TGGTGGTGGTGG
>pdb|7Y7T|C Chain C, QDE-1 in complex with 12nt DNA template, ATP and 3'-dGTP
GAGAGACCTTTT
>pdb|7R06|L Chain L, Abortive infection DNA polymerase AbiK from Lactococcus lactis
CCCCCCCCCCCC
>pdb|7R06|K Chain K, Abortive infection DNA polymerase AbiK from Lactococcus lactis
CCCCCCCCCCCC
>pdb|7R06|J Chain J, Abortive infection DNA polymerase AbiK from Lactococcus lactis
CCCCCCCCCCCC
>pdb|7R06|I Chain I, Abortive infection DNA polymerase AbiK from Lactococcus lactis
CCCCCCCCCCCC
>pdb|7R06|H Chain H, Abortive infection DNA polymerase AbiK from Lactococcus lactis
CCCCCCCCCCCC
>pdb|7R06|G Chain G, Abortive infection DNA polymerase AbiK from Lactococcus lactis
CCCCCCCCCCCC
>PA550757.1 WO 2022138707-A/1: A pharmaceutical composition for treating amyotrophic lateral sclerosis
ACATCACTCCGT
>PA549975.1 WO 2022124148-A/6: Method for nucleic acid detection, compounds, and fluorescent probe
CTTTTGCAAAAG
>PA548409.1 JP 2022095266-A/5: Nucleic acid conatructs, Kits, Detection method and Methods for predicting therapeutic effects
CATTTCGACCAC
>PA548407.1 JP 2022095266-A/3: Nucleic acid conatructs, Kits, Detection method and Methods for predicting therapeutic effects
GGTCATGATGAC
>PA548405.1 JP 2022095266-A/1: Nucleic acid conatructs, Kits, Detection method and Methods for predicting therapeutic effects
GAGGTCATTATG
>pdb|7NE6|C Chain C, Human TET2 in complex with unfavourable DNA substrate.
NCAGGNGCCTGT
>pdb|7NE6|B Chain B, Human TET2 in complex with unfavourable DNA substrate.
ACAGGNGCCTGT
>pdb|7NE3|C Chain C, Human TET2 in complex with favourable DNA substrate.
NCACANGTGTGT
>pdb|7NE3|B Chain B, Human TET2 in complex with favourable DNA substrate.
NCACANGTGTGT
>PA547842.1 JP 2022523148-A/66: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
GTTCTCAGTGTG
>PA547823.1 JP 2022523148-A/47: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CGGGTCATAATC
>PA547104.1 WO 2022102791-A/8: Novel linker and method for detecting antigen by using thereof
GGGGGAGGCAGC
>PA545692.1 WO 2022092132-A/20: Petide tag and tagged protein comprising the same
TCTAAAATAAAA
>PA545690.1 WO 2022092132-A/18: Petide tag and tagged protein comprising the same
GCTAAAAATCCA
>PA545689.1 WO 2022092132-A/17: Petide tag and tagged protein comprising the same
ATTAAAAATCCA
>PA545688.1 WO 2022092132-A/16: Petide tag and tagged protein comprising the same
CGTAAAAATCCA
>PA545687.1 WO 2022092132-A/15: Petide tag and tagged protein comprising the same
CGTAATAAACCA
>PA545686.1 WO 2022092132-A/14: Petide tag and tagged protein comprising the same
TGGAATAAACCA
>PA545685.1 WO 2022092132-A/13: Petide tag and tagged protein comprising the same
TTTAATAAACCA
>PA545684.1 WO 2022092132-A/12: Petide tag and tagged protein comprising the same
GTTAATAAACCA
>PA545683.1 WO 2022092132-A/11: Petide tag and tagged protein comprising the same
GCTAATAAACCA
>PA545682.1 WO 2022092132-A/10: Petide tag and tagged protein comprising the same
ATGAATAAACCA
>PA545681.1 WO 2022092132-A/9: Petide tag and tagged protein comprising the same
ATTAATAAACCA
>PA545680.1 WO 2022092132-A/8: Petide tag and tagged protein comprising the same
TTTAAACCAGGT
>PA545679.1 WO 2022092132-A/7: Petide tag and tagged protein comprising the same
TATAAACCAGGT
>PA545678.1 WO 2022092132-A/6: Petide tag and tagged protein comprising the same
TGTAAACCAGGT
>PA545677.1 WO 2022092132-A/5: Petide tag and tagged protein comprising the same
ATGAAACCAGGT
>PA545676.1 WO 2022092132-A/4: Petide tag and tagged protein comprising the same
AATAAACCAGGT
>PA545675.1 WO 2022092132-A/3: Petide tag and tagged protein comprising the same
ATTAAACCAGGT
>PA545674.1 WO 2022092132-A/2: Petide tag and tagged protein comprising the same
CGTAAACCAGGT
>PA545673.1 WO 2022092132-A/1: Petide tag and tagged protein comprising the same
CATAAACCAGGT
>pdb|7S81|D Chain D, Structure of human PARP1 domains (Zn1, Zn3, WGR, HD) bound to a DNA double strand break.
ATGCGGCCGCAT
>pdb|7S81|E Chain E, Structure of human PARP1 domains (Zn1, Zn3, WGR, HD) bound to a DNA double strand break.
ATGCGGCCGCAT
>pdb|7S81|L Chain L, Structure of human PARP1 domains (Zn1, Zn3, WGR, HD) bound to a DNA double strand break.
ATGCGGCCGCAT
>pdb|7S81|M Chain M, Structure of human PARP1 domains (Zn1, Zn3, WGR, HD) bound to a DNA double strand break.
ATGCGGCCGCAT
>pdb|7R6V|M Chain M, Human EXOG complexed with dRP-containing DNA
CGCACGTCAGAA
>pdb|7R6V|L Chain L, Human EXOG complexed with dRP-containing DNA
CGCACGTCAGAA
>pdb|7R6V|A Chain A, Human EXOG complexed with dRP-containing DNA
CGCACGTCAGAA
>pdb|7R6V|B Chain B, Human EXOG complexed with dRP-containing DNA
CGCACGTCAGAA
>pdb|8DR7|J Chain J, Open state of RFC:PCNA bound to a nicked dsDNA
NGCCCCCCCGGC
>pdb|8DR5|J Chain J, Open state of RFC:PCNA bound to a 3' ss/dsDNA junction (DNA2) with NTD
NGCCCCCCCGGC
>pdb|8DR4|K Chain K, Open state of RFC:PCNA bound to a 3' ss/dsDNA junction (DNA2) without NTD
NAGGGGGGGGGG
>pdb|7SYP|7 Chain 7, Structure of the wt IRES and 40S ribosome binary complex, open conformation. Structure 10(wt)
NAAAAAAAAAAA
>pdb|7XYA|R Chain R, The cryo-EM structure of an AlpA-loading complex
ATATACCCTCGA
>pdb|4PZI|C Chain C, Zinc finger region of MLL2 in complex with CpG DNA
GCCACCGGTGGC
>pdb|4PZI|B Chain B, Zinc finger region of MLL2 in complex with CpG DNA
GCCACCGGTGGC
>pdb|2RU7|B Chain B, Refined structure of RNA aptamer in complex with the partial binding peptide of prion protein
GGAGGAGGAGGA
>pdb|2RU7|A Chain A, Refined structure of RNA aptamer in complex with the partial binding peptide of prion protein
GGAGGAGGAGGA
>pdb|4NW3|C Chain C, Crystal structure of MLL CXXC domain in complex with a CpG DNA
GCCATCGATGGC
>pdb|4NW3|B Chain B, Crystal structure of MLL CXXC domain in complex with a CpG DNA
GCCATCGATGGC
>pdb|6M6S|D Chain D, Crystal structure of Caenorhabditis elegans Dicer-related helicase 3 (DRH-3) C-terminal domain with 5'-ppp 12-mer dsRNA
NGCGCGCGCGCC
>pdb|6M6S|C Chain C, Crystal structure of Caenorhabditis elegans Dicer-related helicase 3 (DRH-3) C-terminal domain with 5'-ppp 12-mer dsRNA
NGCGCGCGCGCC
>PA544615.1 JP 2022519312-A/66: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
GTTCTCAGTGTG
>PA544596.1 JP 2022519312-A/47: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CGGGTCATAATC
>PA544493.1 JP 2022519296-A/66: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
GTTCTCAGTGTG
>PA544474.1 JP 2022519296-A/47: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CGGGTCATAATC
>PA544077.1 WO 2022071492-A/13: Fusion Protein for Suppressing Influenza Virus and Pharmaceutical Composition Comprising Thereof
AAGGATGAGCTT
>PA543983.1 WO 2022071521-A/14: Crosslinked peptide bindable to target peptide, method for produving thereof, and pharmaceutical preparation containing thereof
GGTGGCGGGTCT
>PA543488.1 WO 2022085756-A/1: Tokenized gene sequence generating device, gene corpus generating device and program
ACGAAACAGCGC
>pdb|7FEF|F Chain F, Crystal structure of AtMBD6 with DNA
GCCAANGTTGGC
>pdb|7FEF|E Chain E, Crystal structure of AtMBD6 with DNA
GCCAANGTTGGC
>pdb|5OE1|B Chain B, Im polyamide in complex with 5'CGATGTACATCG3'- hairpin polyamides studies
NGATGTACATCG
>pdb|5OE1|A Chain A, Im polyamide in complex with 5'CGATGTACATCG3'- hairpin polyamides studies
NGATGTACATCG
>pdb|7W5P|F Chain F, Crystal Structure of the dioxygenase CcTet from Coprinopsis cinereain bound to 12bp N6-methyldeoxyadenine (6mA) containing duplex DNA
NGTAGCGGATCG
>pdb|7W5P|E Chain E, Crystal Structure of the dioxygenase CcTet from Coprinopsis cinereain bound to 12bp N6-methyldeoxyadenine (6mA) containing duplex DNA
NGATCNGCTACG
>pdb|7W5P|C Chain C, Crystal Structure of the dioxygenase CcTet from Coprinopsis cinereain bound to 12bp N6-methyldeoxyadenine (6mA) containing duplex DNA
NGTAGCGGATCG
>pdb|7W5P|B Chain B, Crystal Structure of the dioxygenase CcTet from Coprinopsis cinereain bound to 12bp N6-methyldeoxyadenine (6mA) containing duplex DNA
NGATCNGCTACG
>pdb|7JK0|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J1 immobile Holliday junction
GAACGACACTGA
>pdb|7JJZ|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J2 immobile Holliday junction
GAACGACACTGA
>pdb|7JJY|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J3 immobile Holliday junction with R3 symmetry
GAACGACAGTGA
>pdb|7JJX|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J5 immobile Holliday junction with R3 symmetry
GAACGACACCGA
>pdb|7JJW|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J7 immobile Holliday junction with R3 symmetry
GAACGACACAGA
>pdb|7JJ6|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J8 immobile Holliday junction with R3 symmetry
GAACGACACAGA
>pdb|7JJ5|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J10 immobile Holliday junction with R3 symmetry
GAACGACACTGA
>pdb|7JJ4|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J14 immobile Holliday junction with R3 symmetry
GAACGACAGAGA
>pdb|7JJ3|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J16 immobile Holliday junction with R3 symmetry
GAACGACAGTGA
>pdb|7JJ2|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J19 immobile Holliday junction with R3 symmetry
GAACGACAGAGA
>pdb|7JIQ|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J21 immobile Holliday junction with R3 symmetry
GAACGACACTGA
>pdb|7JIP|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J22 immobile Holliday junction with R3 symmetry
GAACGACACTGA
>pdb|7JIO|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J23 immobile Holliday junction with R3 symmetry
GAACGACACTGA
>pdb|7JIN|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J24 immobile Holliday junction with R3 symmetry
GAACGACACAGA
>pdb|7JIM|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J26 immobile Holliday junction with R3 symmetry
GAACGACATTGA
>pdb|7JI9|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J30 immobile Holliday junction with R3 symmetry
GAACGACACTGA
>pdb|7JI8|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J31 immobile Holliday junction with R3 symmetry
GAACGACACAGA
>pdb|7JI7|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J33 immobile Holliday junction with R3 symmetry
GAACGACATTGA
>pdb|7JI6|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J34 immobile Holliday junction with R3 symmetry
GAACGACAAAGA
>pdb|7JI5|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J36 immobile Holliday junction with R3 symmetry
GAACGACAGTGA
>pdb|7JHV|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J36 immobile Holliday junction with R3 symmetry
GAGCAGACGTGA
>pdb|7JHU|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J33 immobile Holliday junction with R3 symmetry
GAGCAGACTTGA
>pdb|7JHT|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J31 immobile Holliday junction with R3 symmetry
GAGCAGACCAGA
>pdb|7JHS|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J5 immobile Holliday junction with R3 symmetry
GAGCAGACCCGA
>pdb|7JHR|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J4 immobile Holliday junction with R3 symmetry
GAGCAGACCAGA
>pdb|7JHC|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J26 immobile Holliday junction
GAGCAGACTTGA
>pdb|7JHB|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J24 immobile Holliday junction
GAGCAGACCAGA
>pdb|7JHA|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J23 immobile Holliday junction
GAGCAGACCTGA
>pdb|7JH9|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J22 immobile Holliday junction
GAGCAGACCTGA
>pdb|7JH8|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J20 immobile Holliday junction
GAGCAGACGTGA
>pdb|7JFX|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J16 immobile Holliday junction
GAGCAGACGTGA
>pdb|7JFW|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J10 immobile Holliday junction
GAGCAGACCTGA
>pdb|7JFV|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J7 immobile Holliday junction
GAGCAGACCAGA
>pdb|7JFU|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J5 immobile Holliday junction
GAGCAGACCCGA
>pdb|7JFT|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J2 immobile Holliday junction
GAGCAGACCTGA
>pdb|6XO9|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J33 immobile Holliday junction
GAGCAGACTTGA
>pdb|6XO8|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J31 immobile Holliday junction
GAGCAGACCAGA
>pdb|6XO7|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J30 immobile Holliday junction
GAGCAGACCTGA
>pdb|6XO6|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J28 immobile Holliday junction
GAGCAGACATGA
>pdb|6XO5|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J8 immobile Holliday junction
GAGCAGACCAGA
>pdb|6XNA|A Chain A, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J1 immobile Holliday junction
GAGCAGACCTGA
>pdb|7KWK|B Chain B, DNA-DB1879 complex: The DNA sequence 5'-CGCGAATTCGCG-3' presents a binding site for the heterocyclic small molecule (DB1879).
CGCGAATTCGCG
>pdb|7KWK|A Chain A, DNA-DB1879 complex: The DNA sequence 5'-CGCGAATTCGCG-3' presents a binding site for the heterocyclic small molecule (DB1879).
CGCGAATTCGCG
>pdb|7OWF|B Chain B, KlenTaq DNA polymerase in a ternary complex with primer/template and the fluorescent nucleotide analog BFdUTP
GACCACGGCCAN
>PA540636.1 JP 2022042243-A/7: DNA detection method
AGGAAAATCCGT
>PA540635.1 JP 2022042243-A/6: DNA detection method
CGCTGTTATCCC
>PA541866.1 WO 2022065413-A/7: Novel Artificial Nucleic Acids, Production Method Thereof and Use
AGCAAAAAACGC
>PA541865.1 WO 2022065413-A/6: Novel Artificial Nucleic Acids, Production Method Thereof and Use
AGCAAAAAACGC
>PA541863.1 WO 2022065413-A/4: Novel Artificial Nucleic Acids, Production Method Thereof and Use
GCGNNNNNNGCT
>PA541862.1 WO 2022065413-A/3: Novel Artificial Nucleic Acids, Production Method Thereof and Use
GCGTTNNNTGCT
>PA541861.1 WO 2022065413-A/2: Novel Artificial Nucleic Acids, Production Method Thereof and Use
GCGNTNTNTGCT
>PA541860.1 WO 2022065413-A/1: Novel Artificial Nucleic Acids, Production Method Thereof and Use
GCGTTNTTTGCT
>pdb|5YTH|B Chain B, Structure of large fragment of DNA Polymerase I from Thermus aquaticus Host-Guest complex with the unnatural base M-fC pair with dG
GACCGCGGCGCN
>pdb|5YTF|B Chain B, Structure of large fragment of DNA Polymerase I from Thermus aquaticus Host-Guest complex with the unnatural base M-fC pair with dA
GACCACGGCGCN
>pdb|5V1K|B Chain B, Structure of R-GNA dodecamer
CGCGAANNAGCG
>pdb|5V1K|A Chain A, Structure of R-GNA dodecamer
CGCGAANNAGCG
>pdb|5V1L|D Chain D, Structure of S-GNA dodecamer
CGCGAATNAGCG
>pdb|5V1L|C Chain C, Structure of S-GNA dodecamer
CGCGAATNAGCG
>pdb|5V1L|B Chain B, Structure of S-GNA dodecamer
CGCGAATNAGCG
>pdb|5V1L|A Chain A, Structure of S-GNA dodecamer
CGCGAATNAGCG
>pdb|7N4E|R Chain R, Escherichia coli sigma 70-dependent paused transcription elongation complex
TTCGGAGAGGTA
>pdb|7SFG|D Chain D, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Cofactor SAM
GCAGGNGGCCTC
>pdb|7SFG|C Chain C, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Cofactor SAM
GAGGCNGCCTGC
>pdb|7SFF|D Chain D, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3852279B
GCAGGNGGCCTC
>pdb|7SFF|C Chain C, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3852279B
GAGGCNGCCTGC
>pdb|7SFE|D Chain D, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3830334A
GCAGGNGGCCTC
>pdb|7SFE|C Chain C, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3830334A
GAGGCNGCCTGC
>pdb|7SFD|D Chain D, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3543105A
GCAGGNGGCCTC
>pdb|7SFD|C Chain C, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3543105A
GAGGCNGCCTGC
>pdb|7SFC|D Chain D, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3735967A
GCAGGNGGCCTC
>pdb|7SFC|C Chain C, Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3735967A
GAGGCNGCCTGC
>pdb|7KU4|B Chain B, DNA-DB818 complex: The DNA sequence 5'-CGCGAATTCGCG-3' presents a binding site for the heterocyclic small molecule (DB818).
CGCGAATTCGCG
>pdb|7KU4|A Chain A, DNA-DB818 complex: The DNA sequence 5'-CGCGAATTCGCG-3' presents a binding site for the heterocyclic small molecule (DB818).
CGCGAATTCGCG
>pdb|7T1B|P Chain P, Rev1 Ternary Complex with rCTP and Ca2+
NGGGTGTGGTAG
>pdb|7T1A|P Chain P, Rev1 Ternary Complex with dATP and Ca2+
GGGGTGTGGTAG
>pdb|7T19|P Chain P, Rev1 Ternary Complex with dGTP and Ca2+
GGGGTGTGGTAG
>pdb|7T18|P Chain P, Rev1 Ternary Complex with dTTP and Ca2+
NGGGTGTGGTAG
>pdb|7Z4O|VVV Chain VVV, Influenza A/H7N9 polymerase core dimer with Pol II pSer5 CTD peptide mimic bound in site 2A
NGTAGTAACAAG
>pdb|7Z4O|UUU Chain UUU, Influenza A/H7N9 polymerase core dimer with Pol II pSer5 CTD peptide mimic bound in site 2A
NGTAGTAACAAG
>pdb|7TXJ|2 Chain 2, Cryo-EM of AFV6
NATATATATATA
>pdb|7TXJ|1 Chain 1, Cryo-EM of AFV6
NATATATATATA
>PA499309.1 JP 2022021924-A/9: agent for suppressing adipogenic differentiation
TGGGTGGGGAAA
>PA499308.1 JP 2022021924-A/8: agent for suppressing adipogenic differentiation
AAGGGTGGGGTT
>PA499302.1 JP 2022021924-A/2: agent for suppressing adipogenic differentiation
TTGGGTGGGGAA
>OF337513.1 KR 1020210124362-A/66: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
GTTCTCAGTGTG
>OF337494.1 KR 1020210124362-A/47: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CGGGTCATAATC
>OF336783.1 KR 1020210126042-A/198: INHIBITION OF UNINTENDED MUTATIONS IN GENE EDITING
GTTTGAGAGCTA
>OF336782.1 KR 1020210126042-A/197: INHIBITION OF UNINTENDED MUTATIONS IN GENE EDITING
GTTTTAGAGCTA
>OF336612.1 KR 1020210111887-A/103: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CATGTCAGAGTC
>OF336609.1 KR 1020210111887-A/100: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTGAGACTGTAC
>OF336590.1 KR 1020210111887-A/81: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
TTTGCTTGCTCT
>OF336589.1 KR 1020210111887-A/80: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GATGCCTGCTCT
>OF336588.1 KR 1020210111887-A/79: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
ATTCGGTGCTCT
>OF336587.1 KR 1020210111887-A/78: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTTCAATGCTCT
>OF336586.1 KR 1020210111887-A/77: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
TCCTGTCGGTTC
>OF336585.1 KR 1020210111887-A/76: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATCGTCCT
>OF336584.1 KR 1020210111887-A/75: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTTGCAC
>OF336583.1 KR 1020210111887-A/74: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATACCTAC
>OF336582.1 KR 1020210111887-A/73: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTTCTAC
>OF336581.1 KR 1020210111887-A/72: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTGCTCT
>OF336580.1 KR 1020210111887-A/71: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTGTGCT
>OF336579.1 KR 1020210111887-A/70: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATGCGATG
>OF336578.1 KR 1020210111887-A/69: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGACCT
>OF336577.1 KR 1020210111887-A/68: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCCGTCCT
>OF336576.1 KR 1020210111887-A/67: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCGTACCT
>OF336575.1 KR 1020210111887-A/66: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCGTTCCT
>OF336574.1 KR 1020210111887-A/65: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCACTCCT
>OF336573.1 KR 1020210111887-A/64: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGTCCT
>OF336572.1 KR 1020210111887-A/63: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGTGCT
>OF336571.1 KR 1020210111887-A/62: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGTACT
>OF336570.1 KR 1020210111887-A/61: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGCTCT
>OF336569.1 KR 1020210111887-A/60: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCGACTCT
>OF336568.1 KR 1020210111887-A/59: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCCTCTCT
>OF336567.1 KR 1020210111887-A/58: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCACCTCT
>OF336566.1 KR 1020210111887-A/57: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGTCCT
>OF336565.1 KR 1020210111887-A/56: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTGCCT
>OF336564.1 KR 1020210111887-A/55: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTGCAC
>OF336563.1 KR 1020210111887-A/54: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCACAAAC
>OF336562.1 KR 1020210111887-A/53: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGAAAC
>OF336561.1 KR 1020210111887-A/52: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGTAAC
>OF336560.1 KR 1020210111887-A/51: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCAACTAC
>OF336559.1 KR 1020210111887-A/50: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTCGAC
>OF336558.1 KR 1020210111887-A/49: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCACTCAC
>OF336557.1 KR 1020210111887-A/48: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCACCTAC
>OF336556.1 KR 1020210111887-A/47: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTCTAC
>OF336555.1 KR 1020210111887-A/46: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCGACTAC
>OF336554.1 KR 1020210111887-A/45: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGCTAC
>OF336553.1 KR 1020210111887-A/44: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTCCTAC
>OF336552.1 KR 1020210111887-A/43: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CATCGCATGCCT
>OF336551.1 KR 1020210111887-A/42: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CACGAACGTCAG
>OF336504.1 KR 1020210123344-A/66: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
GTTCTCAGTGTG
>OF336485.1 KR 1020210123344-A/47: METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CGGGTCATAATC
>OF334133.1 KR 1020210151049-A/469: TREM COMPOSITIONS AND USES THEREOF
CGCCTTAGGTGT
>OF331819.1 KR 1020210126012-A/17: CAS12A GUIDE RNA MOLECULES AND USES THEREOF
TCTACTTGTAGA
>OF330261.1 KR 1020210133215-A/24: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
CCCATCTCGGAA
>OF330260.1 KR 1020210133215-A/23: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
CGGAACGTGGTA
>OF330259.1 KR 1020210133215-A/22: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
GGCAAAAATGCG
>OF330258.1 KR 1020210133215-A/21: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
GTTCAGCTCCAG
>OF327869.1 KR 1020210108426-A/129: COMPOSITIONS AND METHODS FOR DETECTING PLASMODIUM SPECIES NUCLEIC ACID
GTATTCGCGCAA
>OF325978.1 KR 1020210102309-A/51: REDUCED AND MINIMAL MANIPULATION MANUFACTURING OF GENETICALLY-MODIFIED CELLS
TTTGCCTTGTCA
>OF324658.1 KR 1020210105914-A/49: NUCLEASE-MEDIATED REPEAT EXPANSION
AGTCAGTCAGTC
>OF324626.1 KR 1020210105914-A/12: NUCLEASE-MEDIATED REPEAT EXPANSION
CCCCGCCCCGCG
>OF321793.1 KR 1020210113597-A/498: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GATCTTGACTTG
>OF321516.1 KR 1020210093977-A/47: SUICIDE GENE
GGCTACCTTGTC
>OF321513.1 KR 1020210093977-A/44: SUICIDE GENE
TGATCTTGCCTG
>OF360518.1 KR 1020210158870-A/6: METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDS
GCATACGTGATG
>OF360495.1 KR 1020210158859-A/23: UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE
AGCAGGATGAAG
>OF357189.1 KR 1020210141773-A/3: SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
TTTTGCCGCGCC
>OF357188.1 KR 1020210141773-A/1: SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
TTTTGCCGCGCC
>OF315033.1 KR 1020210091180-A/10616: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF315020.1 KR 1020210091180-A/10603: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF315007.1 KR 1020210091180-A/10590: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF314919.1 KR 1020210091180-A/10502: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF314911.1 KR 1020210091180-A/10494: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF314903.1 KR 1020210091180-A/10486: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF314896.1 KR 1020210091180-A/10479: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF314889.1 KR 1020210091180-A/10472: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF314881.1 KR 1020210091180-A/10464: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF314870.1 KR 1020210091180-A/10453: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF314857.1 KR 1020210091180-A/10440: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF314830.1 KR 1020210091180-A/10413: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF314820.1 KR 1020210091180-A/10403: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF314810.1 KR 1020210091180-A/10393: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF314798.1 KR 1020210091180-A/10381: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF314785.1 KR 1020210091180-A/10368: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF314773.1 KR 1020210091180-A/10356: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF314761.1 KR 1020210091180-A/10344: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF314749.1 KR 1020210091180-A/10332: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF314737.1 KR 1020210091180-A/10320: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF314724.1 KR 1020210091180-A/10307: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF314711.1 KR 1020210091180-A/10294: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF314698.1 KR 1020210091180-A/10281: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF354971.1 KR 1020210143855-A/65: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGGAGCTCCCAG
>OF354967.1 KR 1020210143855-A/61: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGCAGCTCCCAA
>OF354963.1 KR 1020210143855-A/57: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTAGTTCTCAG
>OF354959.1 KR 1020210143855-A/53: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGGAGTAGTCAG
>OF354955.1 KR 1020210143855-A/49: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGAAGCAGCCAG
>OF354951.1 KR 1020210143855-A/45: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGCTCATCACAG
>OF354947.1 KR 1020210143855-A/41: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGCTCCTCCCAG
>OF354943.1 KR 1020210143855-A/37: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTTCTTCTCAG
>OF354939.1 KR 1020210143855-A/33: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTTCGTCGCAG
>OF354915.1 KR 1020210143855-A/9: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTTCATCACAA
>OF354935.1 KR 1020210143855-A/29: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGGTCCTCCCAA
>OF354931.1 KR 1020210143855-A/25: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGATCTTCTCAA
>OF354927.1 KR 1020210143855-A/21: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGCTCGTCGCAA
>OF354923.1 KR 1020210143855-A/17: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGCAGTAGTCAA
>OF354919.1 KR 1020210143855-A/13: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTAGCAGCCAA
>OF314688.1 KR 1020210091180-A/10271: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF314676.1 KR 1020210091180-A/10259: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF314660.1 KR 1020210091180-A/10243: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF314647.1 KR 1020210091180-A/10230: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF314634.1 KR 1020210091180-A/10217: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF314546.1 KR 1020210091180-A/10129: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF314538.1 KR 1020210091180-A/10121: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF314530.1 KR 1020210091180-A/10113: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF314523.1 KR 1020210091180-A/10106: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF314497.1 KR 1020210091180-A/10080: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF314516.1 KR 1020210091180-A/10099: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF314508.1 KR 1020210091180-A/10091: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF314484.1 KR 1020210091180-A/10067: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF314457.1 KR 1020210091180-A/10040: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF314447.1 KR 1020210091180-A/10030: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF314437.1 KR 1020210091180-A/10020: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF314425.1 KR 1020210091180-A/10008: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF314412.1 KR 1020210091180-A/9995: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF314400.1 KR 1020210091180-A/9983: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF314388.1 KR 1020210091180-A/9971: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF314376.1 KR 1020210091180-A/9959: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF314364.1 KR 1020210091180-A/9947: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF314351.1 KR 1020210091180-A/9934: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF314338.1 KR 1020210091180-A/9921: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF314325.1 KR 1020210091180-A/9908: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF314315.1 KR 1020210091180-A/9898: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF314303.1 KR 1020210091180-A/9886: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF314287.1 KR 1020210091180-A/9870: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF314274.1 KR 1020210091180-A/9857: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF314261.1 KR 1020210091180-A/9844: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF314173.1 KR 1020210091180-A/9756: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF314165.1 KR 1020210091180-A/9748: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF314157.1 KR 1020210091180-A/9740: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF314150.1 KR 1020210091180-A/9733: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF314143.1 KR 1020210091180-A/9726: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF314135.1 KR 1020210091180-A/9718: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF314124.1 KR 1020210091180-A/9707: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF314111.1 KR 1020210091180-A/9694: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF314084.1 KR 1020210091180-A/9667: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF314074.1 KR 1020210091180-A/9657: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF314064.1 KR 1020210091180-A/9647: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF314052.1 KR 1020210091180-A/9635: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF314039.1 KR 1020210091180-A/9622: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF314027.1 KR 1020210091180-A/9610: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF314015.1 KR 1020210091180-A/9598: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF314003.1 KR 1020210091180-A/9586: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF313991.1 KR 1020210091180-A/9574: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF313978.1 KR 1020210091180-A/9561: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF313965.1 KR 1020210091180-A/9548: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF313952.1 KR 1020210091180-A/9535: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF313942.1 KR 1020210091180-A/9525: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF313930.1 KR 1020210091180-A/9513: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF313914.1 KR 1020210091180-A/9497: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF313901.1 KR 1020210091180-A/9484: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF313888.1 KR 1020210091180-A/9471: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF313800.1 KR 1020210091180-A/9383: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF313792.1 KR 1020210091180-A/9375: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF313784.1 KR 1020210091180-A/9367: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF313777.1 KR 1020210091180-A/9360: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF313770.1 KR 1020210091180-A/9353: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF313762.1 KR 1020210091180-A/9345: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF313751.1 KR 1020210091180-A/9334: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF313738.1 KR 1020210091180-A/9321: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF313711.1 KR 1020210091180-A/9294: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF313701.1 KR 1020210091180-A/9284: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF313691.1 KR 1020210091180-A/9274: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF313679.1 KR 1020210091180-A/9262: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF313666.1 KR 1020210091180-A/9249: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF313654.1 KR 1020210091180-A/9237: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF313642.1 KR 1020210091180-A/9225: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF313630.1 KR 1020210091180-A/9213: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF313618.1 KR 1020210091180-A/9201: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF313605.1 KR 1020210091180-A/9188: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF313592.1 KR 1020210091180-A/9175: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF313579.1 KR 1020210091180-A/9162: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF313569.1 KR 1020210091180-A/9152: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF313557.1 KR 1020210091180-A/9140: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF313541.1 KR 1020210091180-A/9124: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF313528.1 KR 1020210091180-A/9111: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF313515.1 KR 1020210091180-A/9098: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF313427.1 KR 1020210091180-A/9010: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF313419.1 KR 1020210091180-A/9002: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF313411.1 KR 1020210091180-A/8994: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF313404.1 KR 1020210091180-A/8987: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF313397.1 KR 1020210091180-A/8980: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF313389.1 KR 1020210091180-A/8972: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF313378.1 KR 1020210091180-A/8961: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF313365.1 KR 1020210091180-A/8948: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF313338.1 KR 1020210091180-A/8921: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF313328.1 KR 1020210091180-A/8911: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF313318.1 KR 1020210091180-A/8901: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF313306.1 KR 1020210091180-A/8889: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF313293.1 KR 1020210091180-A/8876: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF313281.1 KR 1020210091180-A/8864: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF313269.1 KR 1020210091180-A/8852: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF313257.1 KR 1020210091180-A/8840: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF313245.1 KR 1020210091180-A/8828: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF313232.1 KR 1020210091180-A/8815: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF313219.1 KR 1020210091180-A/8802: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF313206.1 KR 1020210091180-A/8789: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF313196.1 KR 1020210091180-A/8779: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF313184.1 KR 1020210091180-A/8767: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF313168.1 KR 1020210091180-A/8751: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF313054.1 KR 1020210091180-A/8637: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF313046.1 KR 1020210091180-A/8629: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF313038.1 KR 1020210091180-A/8621: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF313031.1 KR 1020210091180-A/8614: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF313024.1 KR 1020210091180-A/8607: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF313016.1 KR 1020210091180-A/8599: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF313005.1 KR 1020210091180-A/8588: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF312992.1 KR 1020210091180-A/8575: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF312965.1 KR 1020210091180-A/8548: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF312955.1 KR 1020210091180-A/8538: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF312945.1 KR 1020210091180-A/8528: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF312933.1 KR 1020210091180-A/8516: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF312920.1 KR 1020210091180-A/8503: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF312908.1 KR 1020210091180-A/8491: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF313155.1 KR 1020210091180-A/8738: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF313142.1 KR 1020210091180-A/8725: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF312896.1 KR 1020210091180-A/8479: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF312884.1 KR 1020210091180-A/8467: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF312872.1 KR 1020210091180-A/8455: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF312859.1 KR 1020210091180-A/8442: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF312846.1 KR 1020210091180-A/8429: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF312833.1 KR 1020210091180-A/8416: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF312823.1 KR 1020210091180-A/8406: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF312811.1 KR 1020210091180-A/8394: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF312795.1 KR 1020210091180-A/8378: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF312782.1 KR 1020210091180-A/8365: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF312769.1 KR 1020210091180-A/8352: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF352890.1 KR 1020210143230-A/819: METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES
TGCAGTGTTCAC
>OF352889.1 KR 1020210143230-A/818: METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES
ACTGCAAGTGCA
>OF312681.1 KR 1020210091180-A/8264: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF312673.1 KR 1020210091180-A/8256: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF312664.1 KR 1020210091180-A/8247: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF312656.1 KR 1020210091180-A/8239: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF312646.1 KR 1020210091180-A/8229: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF312635.1 KR 1020210091180-A/8218: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF312624.1 KR 1020210091180-A/8207: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF312611.1 KR 1020210091180-A/8194: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF312584.1 KR 1020210091180-A/8167: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF312574.1 KR 1020210091180-A/8157: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF312514.1 KR 1020210091180-A/8097: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF312526.1 KR 1020210091180-A/8109: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF312502.1 KR 1020210091180-A/8085: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF312564.1 KR 1020210091180-A/8147: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF312490.1 KR 1020210091180-A/8073: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF312552.1 KR 1020210091180-A/8135: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF312477.1 KR 1020210091180-A/8060: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF312539.1 KR 1020210091180-A/8122: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF312464.1 KR 1020210091180-A/8047: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF312451.1 KR 1020210091180-A/8034: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF312441.1 KR 1020210091180-A/8024: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF312429.1 KR 1020210091180-A/8012: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF312413.1 KR 1020210091180-A/7996: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF312400.1 KR 1020210091180-A/7983: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF312387.1 KR 1020210091180-A/7970: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF312299.1 KR 1020210091180-A/7882: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF312291.1 KR 1020210091180-A/7874: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF312282.1 KR 1020210091180-A/7865: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF312274.1 KR 1020210091180-A/7857: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF312264.1 KR 1020210091180-A/7847: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF312253.1 KR 1020210091180-A/7836: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF312242.1 KR 1020210091180-A/7825: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF312229.1 KR 1020210091180-A/7812: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF312202.1 KR 1020210091180-A/7785: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF312192.1 KR 1020210091180-A/7775: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF312182.1 KR 1020210091180-A/7765: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF312170.1 KR 1020210091180-A/7753: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF312157.1 KR 1020210091180-A/7740: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF312144.1 KR 1020210091180-A/7727: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF312132.1 KR 1020210091180-A/7715: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF312120.1 KR 1020210091180-A/7703: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF312108.1 KR 1020210091180-A/7691: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF312095.1 KR 1020210091180-A/7678: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF312082.1 KR 1020210091180-A/7665: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF312069.1 KR 1020210091180-A/7652: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF312059.1 KR 1020210091180-A/7642: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF312047.1 KR 1020210091180-A/7630: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF312031.1 KR 1020210091180-A/7614: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF312018.1 KR 1020210091180-A/7601: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF312005.1 KR 1020210091180-A/7588: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF311917.1 KR 1020210091180-A/7500: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF311909.1 KR 1020210091180-A/7492: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF311900.1 KR 1020210091180-A/7483: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF311892.1 KR 1020210091180-A/7475: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF311882.1 KR 1020210091180-A/7465: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF311871.1 KR 1020210091180-A/7454: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF311860.1 KR 1020210091180-A/7443: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF311847.1 KR 1020210091180-A/7430: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF311820.1 KR 1020210091180-A/7403: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF311810.1 KR 1020210091180-A/7393: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF311800.1 KR 1020210091180-A/7383: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF311788.1 KR 1020210091180-A/7371: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF311775.1 KR 1020210091180-A/7358: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF311762.1 KR 1020210091180-A/7345: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF311750.1 KR 1020210091180-A/7333: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF311738.1 KR 1020210091180-A/7321: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF311726.1 KR 1020210091180-A/7309: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF311713.1 KR 1020210091180-A/7296: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF311700.1 KR 1020210091180-A/7283: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF311687.1 KR 1020210091180-A/7270: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF311677.1 KR 1020210091180-A/7260: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF311665.1 KR 1020210091180-A/7248: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF311649.1 KR 1020210091180-A/7232: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF311636.1 KR 1020210091180-A/7219: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF311623.1 KR 1020210091180-A/7206: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF311535.1 KR 1020210091180-A/7118: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF311527.1 KR 1020210091180-A/7110: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF311518.1 KR 1020210091180-A/7101: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF311510.1 KR 1020210091180-A/7093: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF311500.1 KR 1020210091180-A/7083: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF311489.1 KR 1020210091180-A/7072: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF311478.1 KR 1020210091180-A/7061: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF311465.1 KR 1020210091180-A/7048: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF311305.1 KR 1020210091180-A/6888: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF311295.1 KR 1020210091180-A/6878: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF311283.1 KR 1020210091180-A/6866: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF311438.1 KR 1020210091180-A/7021: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF311267.1 KR 1020210091180-A/6850: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF311428.1 KR 1020210091180-A/7011: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF311418.1 KR 1020210091180-A/7001: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF311254.1 KR 1020210091180-A/6837: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF311406.1 KR 1020210091180-A/6989: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF311241.1 KR 1020210091180-A/6824: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF311393.1 KR 1020210091180-A/6976: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF311380.1 KR 1020210091180-A/6963: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF311368.1 KR 1020210091180-A/6951: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF311356.1 KR 1020210091180-A/6939: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF311344.1 KR 1020210091180-A/6927: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF311331.1 KR 1020210091180-A/6914: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF311318.1 KR 1020210091180-A/6901: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF311153.1 KR 1020210091180-A/6736: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF311145.1 KR 1020210091180-A/6728: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF311136.1 KR 1020210091180-A/6719: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF311128.1 KR 1020210091180-A/6711: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF311118.1 KR 1020210091180-A/6701: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF311107.1 KR 1020210091180-A/6690: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF311096.1 KR 1020210091180-A/6679: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF311083.1 KR 1020210091180-A/6666: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF311056.1 KR 1020210091180-A/6639: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF311046.1 KR 1020210091180-A/6629: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF311036.1 KR 1020210091180-A/6619: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF311024.1 KR 1020210091180-A/6607: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF311011.1 KR 1020210091180-A/6594: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF310998.1 KR 1020210091180-A/6581: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF310986.1 KR 1020210091180-A/6569: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF310974.1 KR 1020210091180-A/6557: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF310962.1 KR 1020210091180-A/6545: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF310949.1 KR 1020210091180-A/6532: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF310936.1 KR 1020210091180-A/6519: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF310923.1 KR 1020210091180-A/6506: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF310913.1 KR 1020210091180-A/6496: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF310901.1 KR 1020210091180-A/6484: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF310885.1 KR 1020210091180-A/6468: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF310872.1 KR 1020210091180-A/6455: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF310859.1 KR 1020210091180-A/6442: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF310771.1 KR 1020210091180-A/6354: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF310763.1 KR 1020210091180-A/6346: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF310754.1 KR 1020210091180-A/6337: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF310746.1 KR 1020210091180-A/6329: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF310736.1 KR 1020210091180-A/6319: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF310725.1 KR 1020210091180-A/6308: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF310714.1 KR 1020210091180-A/6297: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF310701.1 KR 1020210091180-A/6284: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF310674.1 KR 1020210091180-A/6257: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF310664.1 KR 1020210091180-A/6247: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF310654.1 KR 1020210091180-A/6237: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF310642.1 KR 1020210091180-A/6225: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF310629.1 KR 1020210091180-A/6212: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF310616.1 KR 1020210091180-A/6199: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF310604.1 KR 1020210091180-A/6187: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF310592.1 KR 1020210091180-A/6175: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF310580.1 KR 1020210091180-A/6163: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF310567.1 KR 1020210091180-A/6150: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF310554.1 KR 1020210091180-A/6137: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF310541.1 KR 1020210091180-A/6124: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF310531.1 KR 1020210091180-A/6114: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF310519.1 KR 1020210091180-A/6102: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF310503.1 KR 1020210091180-A/6086: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF310490.1 KR 1020210091180-A/6073: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF310477.1 KR 1020210091180-A/6060: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF310389.1 KR 1020210091180-A/5972: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF310381.1 KR 1020210091180-A/5964: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF310373.1 KR 1020210091180-A/5956: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF310366.1 KR 1020210091180-A/5949: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF310359.1 KR 1020210091180-A/5942: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF310351.1 KR 1020210091180-A/5934: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF310338.1 KR 1020210091180-A/5921: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF310325.1 KR 1020210091180-A/5908: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF310298.1 KR 1020210091180-A/5881: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF310288.1 KR 1020210091180-A/5871: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF310278.1 KR 1020210091180-A/5861: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
>OF310266.1 KR 1020210091180-A/5849: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCT
>OF310253.1 KR 1020210091180-A/5836: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTG
>OF310241.1 KR 1020210091180-A/5824: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGT
>OF310229.1 KR 1020210091180-A/5812: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTC
>OF310217.1 KR 1020210091180-A/5800: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCC
>OF310205.1 KR 1020210091180-A/5788: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCA
>OF310192.1 KR 1020210091180-A/5775: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAA
>OF310179.1 KR 1020210091180-A/5762: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAG
>OF310166.1 KR 1020210091180-A/5749: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCC
>OF310156.1 KR 1020210091180-A/5739: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCC
>OF310115.1 KR 1020210091180-A/5698: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGA
>OF310102.1 KR 1020210091180-A/5685: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAG
>OF310014.1 KR 1020210091180-A/5597: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTC
>OF310006.1 KR 1020210091180-A/5589: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTT
>OF309998.1 KR 1020210091180-A/5581: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATT
>OF309991.1 KR 1020210091180-A/5574: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCAT
>OF309984.1 KR 1020210091180-A/5567: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCA
>OF309976.1 KR 1020210091180-A/5559: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGC
>OF309963.1 KR 1020210091180-A/5546: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGG
>OF309950.1 KR 1020210091180-A/5533: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATG
>OF310144.1 KR 1020210091180-A/5727: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGC
>OF310128.1 KR 1020210091180-A/5711: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGAT
>OF309923.1 KR 1020210091180-A/5506: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGT
>OF309913.1 KR 1020210091180-A/5496: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTT
>OF309903.1 KR 1020210091180-A/5486: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTC
